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In the history of public health vaccines have proven to be among the most effective disease 
prevention tools. It is clear that in the fight against HIV that new and powerful preventive 
technology such as a vaccine is badly needed. Ethically, however the processes of developing a 
vaccine against HIV have been distinctly different from that of any previous pharmaceutical 
products. HIV vaccine trials can be ethically complex for a number of reasons. In 2004 the HIV 
I AIDS Vaccine Ethics Group undertook a research initiative that aimed to collect data from various 
South African stake holders of HIV vaccine trials to ascertain what they perceived as the ethical 
challenges related to HIV vaccine trials. A quantitative content analysis on the data from 31 semi-
structured interviews revealed that the ethical issue listed spontaneously by most of the respondents 
was that of informed consent. Further probing and discussion on informed consent identified a 
number of sub issues which the respondents thought would pose important challenges to HIV 
vaccine trials in the South African context. 
This study undertook to do a more in-depth qualitative analysis of the data to ascertain whether the 
challenges and concerns the stakeholders have are consistent with or different to those already 
identified in the literature and ethical guidelines on informed consent in medical research. What 
variables may be impacting on the position stakeholders take was also of interest. Results indicated 
that many concerns relating to the substantive and procedural elements of informed consent were 
consistent with those debated in the literature. These issues related to first person consent, the 
voluntariness of participants' consent, practicing cultural sensitivity, dealing with language issues, 
promoting and assessing understanding of material disclosed, issues around the vulnerability of .. 
participants, children and adolescents' capacity to consent and the role of the media. More specific 
to the South African context, stakeholders were concerned about the legal framework under which 
the trials take place, the general lack of education and training about HIV vaccine trials, a lack of 
communication and coordination between stakeholder groups, and the historical influences of 
apartheid on black South African participants' capacity to consent. The main variables that 
appeared to impact on the position stakeholders took related to the role the stakeholders play within 
the trials, the philosophical position underpinning their ethical viewpoints, stakeholders' 
understanding of vulnerability and capacity to consent, and how they view the universality or 







In the history of public health vaccines have proven to be among the most 
effective disease prevention tools. The eradication or control of diseases such 
as small pox, measles and polio, for example, through mass vaccination, is 
evidence of the efficacy of vaccines (Langan & Collins, 1998). It is clear that 
in the fight against HIV new and powerful preventive technology such as a 
vaccine is badly needed (ibid). Numerous vaccine concepts, based on diverse 
biological pathways, have been developed as part of the collaborative, 
international attempt to develop an effective HIV vaccine (Lindegger, 
Milford, Ranchod & Slack, 2006).  
 
Ethically, however the processes of developing an HIV vaccine have been 
distinctly different from that of any previous pharmaceutical product (Langan 
& Collins, 1998). A number of reasons have been posited for this. Slack, 
Lindegger, Vardas, Richter, Strode & Wassenaar (2000) argue that ethical 
problems associated with HIV vaccine trials relate to the relationship between 
science and ethics, whereby requests for people to participate in studies with 
little likelihood of producing meaningful results, are likely to be considered 
unethical.  In addition, they argue that the bioethical principles of autonomy, 
beneficence and justice tend to be approached as add-ons to scientific 
procedures rather than intrinsic to them, which is problematic since these 
ethical principles guide decision making in biomedical research and often 
need balancing in complex ways. For example, reward for participation may 
be a legitimate benefit but should not be great enough to constitute undue 
influence (ibid) which impairs participants‟ autonomy. 
 
HIV vaccine trials can be ethically complex as they tend to involve 
partnerships between sponsors drawn from resource rich nations and 
communities and participants drawn from host nations with limited resources 







(Slack, Stobie, Milford, Lindegger, Wassenaar, Strode & IJsselmiuden, 2004) 
and thus limited power. In addition, most existing vaccine research resides 
within the private sector whereas most research into an HIV vaccine has taken 
place (or funded from) within the public sector (Tucker & Mazithulela, 2004). 
Thus, many more stakeholders are involved and need to be considered. 
 
Lindegger et al. (2006) found that while HIV vaccine trials “share all the 
characteristics of other clinical trials; they may be viewed as somewhat 
distinctive because of the highly vulnerable populations required for phase III 
trials” (p. 716). This vulnerability, they argue, derives from the fact that the 
populations needed for Phase III trials- populations at high risk of HIV 
infection- are also commonly characterized by high levels of poverty, 
relatively low levels of formal education, and poor access to resources.  
 
In 2002 approximately 80 HIV preventative vaccines had been tested world 
wide (Weidle, Mastro, Grant, Nkengasong & Macharia, 2002) with 24 HIV 
vaccine trials collectively involving 19 different vaccines, by 2003 (IAVI, 
2003).  Figures released by IAVI (2008) indicate that this figure increased to 
as many as 120 trials by 2008. Currently PHASE I - small trials in low-risk 
populations to test vaccine safety and immunogenicity- HIV vaccine trials are 
still in progress, with 64 trials still underway in the US, and 27 trials 
underway in Switzerland, Sweden, the United Kingdom, Peru, Brazil, 
Thailand, China, Puerto Rico, Haiti, Germany, Russia, Belgium, India, 
Ruwanda, Kenya, and Uganda, collectively. PHASE II - Small trials moving 
into mid-sized trials in low- and high-risk populations to test vaccine safety 
and immunogenicity- are currently underway, with 17 in the US, 6 in South 
Africa, 6 in France, 3 in Brazil and 1 each in Kenya, Uganda, Tanzania, 
Thailand, Haiti and Jamaica. Eight PHASE III - Large trials in high-risk 
populations to test vaccine efficacy- reportedly started in Thailand October 
2003 and are still in progress. 
 
Weidle et al., have argued for the desperate need for HIV vaccine 
development in Africa in light of the fact that “although there had been more 
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than 45 million cumulative HIV infections in Africa by the end of 2001, there 
have been only two small, phase I, preventive HIV vaccine trials in the 
continent most severely affected by the epidemic” (p. 2263). Although not 
comparable to the US there has been some headway in the development and 
testing of preventative HIV vaccines in Africa. For example, the latest update 
given by the South African Aids Vaccine Initiative (SAAVI) (2008) reports 
the completion of 4 PHASE 1 trials and one PHASE 11 trial, with one of the 
PHASE 11 trials involving 3000 participants having been stopped in October 
2007. An additional 2 PHASE 11 trials were started in 2006 and are still 
underway with an additional PHASE 11 trial still in the planning stage. 
 
In view of the potential ethical challenges related specifically to HIV vaccine 
trials, and following extensive international consultation, UNAIDS developed 
and published ethical guidelines for HIV vaccine trials (UNAIDS, 2000, in 
Lindegger et al., 2006). In South Africa, as part of the South African AIDS 
Vaccine Initiative (SAAVI), the HIV/AIDS Vaccine Ethics Group (HAVEG) 
was established to undertake research and training in the bioethics of HIV 
vaccine trials, and were later commissioned by the Medical Research Council 
to coordinate the development of ethical guidelines for these trials (Lindegger 
et al., 2006). These have been published as the Medical Research Council 
(2003) Guidelines on Ethics for Medical Research: HIV Preventive Vaccine 





Although the literature speculates some potentially problematic ethical issues 
related to HIV vaccine trials what the various stakeholders actually involved 
in the trials believe the existing and potential ethical challenges to be has not 
yet been addressed. To gain a fuller understanding of what ethical challenges 
are anticipated and currently being experienced by those implementing 
existing HIV vaccine trials in South Africa, HAVEG undertook a research 
initiative with various South African stakeholders to investigate the perceived 




ethical challenges in HIV vaccine trials, including informed consent. The 
study reported in this thesis is a sub-study of the broader HAVEG research, 
and is focused specifically on informed consent in HIV vaccine trials. The 
aims of this study are: 
1. To explore the perceived ethical challenges around informed consent in 
HIV vaccine trials among a range of stakeholders; 
2. To compare these challenges to issues raised in the literature around 
informed consent; 
3. To explore what the factors might be which influence the stakeholders 




1.3.1. Historical overview of Informed consent:  
  
Informed consent is a widely recognized principle of research ethics 
(Lindegger et al., 2006). The current practice of requiring informed consent 
from research participants is relatively new, however (IJsselmuiden & Faden, 
1992). The issue of consent has been at the forefront of bio-medical ethics 
since the Nuremberg trials, which presented horrifying accounts of medical 
experimentation in concentration camps (Beauchamp & Childress, 1994). The 
atrocities committed by Nazi “scientists”, an extreme instance of ignoring the 
value of individual human beings allegedly in the pursuit of knowledge, 
placed much greater emphasis on a person‟s right to accept or refuse 
participation in biomedical research (IJsselmuiden & Faden, 1992). Although 
less dramatic, disrespect for the subjects of medical research was common just 
after the Second World War, reflecting the pervasive paternalistic atmosphere 
in medical practice at that time (IJsselmuiden & Faden, 1992). The study of 
immune reactions to live cancer cells injected into mentally retarded subjects 
and the Tuskegee study of the natural history of untreated syphilis (Faden & 
Beauchamp, 1986), serve as recent examples of unethical research that 
stimulated the development of the current theory and practice of informed 




consent. Although the Nuremburg Code of 1948 and the Declaration of 
Helsinki of 1964 both made the consent of subjects a central requirement of 
ethical research, it was not until the mid 1970s that the practice of requiring 
informed consent for medical research became conventional in the West 
(IJsselmuiden & Faden, 1992). 
 
The fundamental justification for requiring consent from human subjects as a 
matter of public policy was best stated in the Belmont Report of 1978 
(IJsselmuiden & Faden, 1992). Since then, multiple ethical guidelines for 
conducting clinical trials have been developed, including the Declaration of 
Helsinki (1983), the CIOMS guidelines (Council for International 
Organizations of Medical Science, 2002), and others. In South Africa, relevant 
guidelines include the Department of Health‟s (2004) Structures, Principles 
and Processes, and the Department of Health‟s (2000) Good Clinical Practice 
guidelines (Lindegger et al., 2006). 
 
1.3.2. The Meaning of Informed consent: 
 
There are different notions of informed consent reflected in the literature. 
Although recent literature on informed consent has begun to employ 
additional distinctions, often referring to notions such as „genuine informed 
consent‟ or „authentic informed consent‟ (Bhutta, 2004, in Lindegger et al., 
2006, p. 713), Faden and Beauchamp (1986, in  Lindegger et al., 2006) draw a 
useful distinction between a legal and a moral notion of informed consent. 
The former refers to formal consent, based on legal rules, in order to 
indemnify the researcher, whereas, the latter refers to „shared decision 
making‟ (p. 2813). Informed shared decision making has been described as 
“decisions that are shared by doctor and patient and informed by best 
evidence, not only about risks and benefits but also patient specific 
characteristics and values” (Jepson, Hewison, Thompson & Weller, 2005, p. 
194). Katz (1984) warns, however, that viewing informed consent as shared 
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decision making, with informed consent and mutual decision making being 
seen as synonymous, is too reductionistic.  
 
The legal and moral approaches to informed consent lead to different 
decisions and guidelines (Lindeggar & Richter, 2000). For example, to the 
question of how much information should be shared with patients “the legal 
approach, concerned as it is with liability, requires that all technical 
information be disclosed to patients as part of the process of providing legal 
indemnity to medical researchers [while] the moral approach is more 
concerned with facilitating shared decision making, which a burden of excess 
information might undermine, and is based on the belief that the expert does 
not know everything and cannot know what is best for each person in a 
medical trial” (Lindegger & Richter, 2000, p. 314). 
 
Beauchamp and Childress (1994) agree, advocating that informed consent is 
more than shared decision making and needs to be understood as an ongoing 
process. This makes sense when viewing informed consent in relation to their 
conceptualization. In the first sense, informed consent is an autonomous 
authorization by individuals of a medical intervention or of involvement in 
research. In this sense “an informed consent occurs if and only if a patient or 
subject, with substantial understanding and, in substantial absence of control 
by others, intentionally authorizes a professional to do something” (p. 143). In 
the second sense, informed consent can be understood in terms of the social 
rules of consent in institutions that must obtain legally valid consent from 
patients or research subjects before proceeding with therapeutic procedures or 
research. In this sense informed consents are not necessarily autonomous acts 
but refer to institutionally or legally effective authorization, as determined by 
the prevailing rules. A patient or subject can  autonomously authorize an 
intervention, and so give an informed consent in the first sense, without 
effectively authorizing that intervention and thus without giving an informed 




In defining informed consent Beauchamp and Childress (1994) discuss the 
conceptualization of informed consent favoured by most literatures. In most 
instances informed consent is divided into an information component and a 
consent component. The information component refers to disclosure of 
information and comprehension of the information disclosed, while the 
consent component refers to a voluntary decision and agreement to undergo a 
recommended procedure. Furthermore, five elements are presented as the 
building blocks for a definition of informed consent. These include: 
competence, disclosure, understanding, voluntariness, and consent. 
Accordingly, “one gives an informed consent to an intervention if (and 
perhaps only if) one is competent to act, receives a thorough disclosure, 
comprehends the disclosure, acts voluntarily, and consents to the intervention” 
(p. 144). Due to some reservations that this definition only captures basic 
notions about informed consent, Beauchamp and Childress (1994), extend 
their analysis of informed consent to include: 1. Threshold Elements 
(Preconditions) that include: competence (to understand and decide) and 
voluntariness (in deciding). 2. Information Elements that include: disclosure 
(of material information), the recommendation (of a plan), and the 
understanding of these, and 3. Consent Elements that include: a decision (in 
favour of a plan) and authorization (of the chosen plan). 
 
The Nuffield Council on Bioethics (2002), make a distinction between the 
substantive and the procedural aspects of ethical guidelines, the former being 
concerned with the ethical principle per se, the latter with its practical 
implementation (cited in Lindegger et al., 2006) These elements reflect what 
Beauchamp and Childress (1994) refer to as the substantive and procedural 
rules that specify and guide ethical actions.  Substantive rules specify 
principles by giving them more content. For example, a rule that specifies “the 
principle of respect for autonomy” (p. 39) is “Make sure you obtain informed 
consent from all participants before enrolling them into research”, in other 
words allow them to exercise an autonomous choice. Procedural rules 
incorporate the rules and procedures, relevant to the society in which the 




 Using this conceptualization, informed consent can be understood as a 
bioethical rule that comprises of both a substantive element, that covers 
aspects such as competence, and understanding, to specify the bioethical 
principle of autonomy, and a procedural element, that suggests how to 
disclose information, assess understanding, ensure voluntariness and help 
participants make a decision and consent in ways that ensure the practice of 
autonomy in biomedical research. The remaining section will discuss 
informed consent and it‟s implications for HIV vaccine trials using this 
formulation as a way of organizing the data, recognizing that there will be 
elements of informed consent, for example cultural issues, that fit into both 
categories.  
 
1.3.3. Considerations related to the substantive element of informed consent: 
 
As stated, informed consent is essentially an ethical code of conduct that 
clarifies ethical responsibilities and offers specific guidelines for ethical 
behaviour (Beauchamp & Childress, 1994). To fully understand and interpret 
what constitutes ethical behaviour, however, Pack-Brown and Williams 
(2003) suggest that there must be an understanding of what an ethical code‟s 
underlying assumptions, principles and goals are. The next section discusses 
the underlying principle of autonomy as well as the moral theories that 
underscore the substantive element of informed consent.   
 
1.3.3.1. The principle of autonomy and Informed consent: 
 
The Belmont report bases the obligation to obtain consent on the ethical 
principle of respect for persons (IJsselmuiden & Faden, 1992) making the 
protection of autonomy and the personal dignity of research subjects the focus 
of the informed consent process. Founded on the philosophical principle of 
autonomy of persons, informed consent requires that researchers respect the 
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right of potential trial participants to self-determination, especially with regard 
to matters pertaining to their own bodies (Beauchamp & Childress, 2001, in 
Lindegger et al., 2006). Vandevelde (2006) describes respect for autonomy as 
the chief value of modern, liberal societies, stating that the main forces which 
have shaped the contemporary debate on autonomy have been put forward by 
philosophers. Disagreements amongst philosophers regarding autonomy 
indicates a need for further analysis of the concept (Beauchamp & Childress, 
2004). The concept of autonomy, of interest to this study, is used by 
Beauchamp and Childress (2004) to examine decision making in health care 
and bio-medical research.   
 
Beauchamp and Childress (2004) distinguish personal autonomy as “personal 
rule of the self that is free from both controlling interferences by others and 
from personal limitations that prevent meaningful choice, such as inadequate 
understanding” (p. 121). Thus an autonomous person freely acts in accordance 
with a freely chosen plan. By contrast, “a person with diminished autonomy, 
is in at least some respect controlled by others or incapable of deliberating or 
acting on the basis of his or her desires and plans” ( p.121). Beauchamp and 
Childress (2004) point out that although theories of autonomy emphasize 
different aspects they all agree that two conditions are essential: (1) liberty 
(independence from controlling forces) and (2) agency (the capacity for 
intentional action) (ibid). 
 
1.3.3.2. The principle of respect for autonomy: 
 
As Beauchamp and Childress (2004) argue, being autonomous is not the same 
as being respected as an autonomous agent. At a minimum, to respect an 
autonomous agent is to acknowledge that person‟s right to hold views, to 
make choices, and to take actions based on personal values and beliefs. Such 
respect involves more than a respectful attitude, it involves respectful action 
that includes obligations to maintain capacities for autonomous choice in 
others, while allaying fears and other conditions that disrupt or destroy their 
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autonomous actions. On this account, respect involves treating persons to 
enable them to act autonomously, whereas, disrespect for autonomy involves 
attitudes and actions that ignore, insult, or demean others‟ autonomy and thus 
deny a minimal equality to persons.  
 
The question is why is such respect owed to persons? Two philosophers, 
Immanuel Kant and John Stuart Mill, who have influenced the contemporary 
debate concerning respect for autonomy (Beauchamp & Childress, 2004) give 
different, yet supporting, interpretations for respecting autonomy. Kant argued 
that respect for autonomy emanates from the recognition that all persons have 
unconditional worth, with each having the capacity to determine his or her 
own destiny (ibid). For Kant, to violate a person‟s autonomy is to treat that 
person merely as a means, in accordance with other‟s goals, without regard for 
that person‟s own goals, which is a fundamental moral violation because 
autonomous persons are ends in themselves capable of determining their own 
destinies (ibid).  
 
Mill, on the other hand, was more concerned about the autonomy of persons 
in shaping their lives, arguing that persons should be allowed to develop 
according to their personal convictions, as long as they do not interfere with a 
like expression of freedom by others. In addition, he insists that there is an 
obligation to persuade others when they have false or ill-considered views 
(ibid). Whereas Mill‟s position requires both non-interference with and an 
active strengthening of autonomous expression, Kant‟s entails a moral 
imperative of respectful treatment of persons as ends rather than merely 
means to an end (ibid). Even though profoundly different, Beauchamp and 








1.3.3.3. Autonomy, authority, and community:  
 
Some writers have argued that autonomous action is incompatible with the 
authority of the church, state, or other communities that traditionally legislate 
people‟s decisions (Beauchamp & Childress, 2004) since persons who choose 
to submit to an authority or to be ruled by others necessarily loose their 
autonomy in doing so. Whereas in some instances autonomy and authority are 
incompatible, Beauchamp and Childress (2004) ague that no fundamental 
inconsistency exists, since “individuals can exercise their autonomy in 
choosing to accept and submit to the authoritative demands of an institution, 
tradition, or community they view as a legitimate source of direction” (p. 
124). Meyers (1989, in Beauchamp & Childress, 2004) questions the model of 
the independent [autonomous] self being presented as a rational will that is 
inattentive to communal life, reciprocity and the development of persons over 
time. He objects to the unrealistic, supreme and overriding value placed on 
autonomy. Beauchamp and Childress (2004) counter this argument by 
suggesting that communal life and human relationships actually provide the 
matrix for the development of the self, a fact that no defensible theory of 
autonomy denies.  
 
Appeals to authority, often in the form of paternalism, can lead to conflict in 
medical research. On one hand, autonomy as a principle of non-interference 
with a right to self-governance, allows every adult to exercise his or her right 
to determine whether to participate in research, while on the other hand, 
paternalism, the interference with, limitation of, or usurpation of individual 
autonomy, usually justified by reasons referring to the welfare or needs of the 
person (Edwards, Kirchin & Huxtable, 2004) overrides their decision to 
participate in research. Paternalism, in the context of research, underscores the 
idea that the research expert knows best, chooses best and does best (ibid) all 
for the welfare of the research participant. Edwards et al. (2004) argue that it 
should be left to competent potential research subjects to make judgments 




Although the assumption is that paternalism is always unjustified in the 
research context, Beauchamp and Childress‟ (2004) definition of paternalism, 
“the intentional overriding of one person‟s known preferences or actions by 
another person, where the person who overrides justifies the action by the goal 
of benefiting or avoiding harm to the person whose will is overridden” (p. 
274), is normatively neutral and does not assume that paternalism is either 
justified or unjustified.  In addition, although the definition assumes an act of 
beneficence it does not assume whether the beneficence is justified, misplaced 
or obligatory (Beauchamp & Childress, 2004).  
 
1.3.3.4. Cultural issues pertaining to Informed consent: 
 
Pack-Brown and Williams (2003) argue that understanding and appreciating 
multicultural ethics requires a “knowledge base built on a historical context of 
the collective studies of philosophers and philosophical ethics over the years” 
(p. 35). In addition to consequentialism (discussed later) they propose three 
other major schools of ethics that also need to be understood when 
considering ethical behaviour in multicultural ethics. These, as described by 
Pack-Brown and Williams (2003), include absolutism, relativism, and 
intentionalism, and will be discussed briefly as follows: 
 
1.3.3.4.1. Absolutism and informed consent: 
 
Absolutism is a school of ethics that upholds the fundamental belief that only 
one truth about human behaviour exists so that differences in perceiving and 
understanding behaviour, particularly within a cultural context, are 
minimized. Ethnocentricism (using one‟s own culture and worldview as the 
basis for judging other cultures and worldviews) and subsequent problems are 
neglected, omitted or discounted when dealing with human behaviour. “When 
and if the need to evaluate evidence of behaviour emerges, those engaging in 
the evaluative process apply the same evaluative criteria across cultures in a 
fixed and unchanging manner … the same measures, strategies, theories, or 
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ethical principles related to human behaviour are to be used in the same way, 
across groups, and without respect for cultural differences” (p. 35). 
Stakeholders of HIV vaccine trials operating from an absolutist position are 
likely to apply the same informed consent procedure in the same way in all 
HIV vaccine trials regardless of the cultural norms, customs, and beliefs 
individual participants ascribe to. 
 
1.3.3.4.2. Relativism and informed consent: 
 
Relativism is a school of ethics that embraces the idea that more than one truth 
exists in the determination of behaviour so that the reality of different 
behaviour and perspectives is acknowledged. Those subscribing to this 
perspective avoid imposing value judgements allowing each cultural context 
and subsequent behaviour to be addressed in its own right. Pack-Brown and 
Williams (2003) describe two types of relativism; descriptive relativism and 
normative relativism. Descriptive relativism is based on the assumption that 
different people have different moral beliefs which affects how they behave 
and define problems. From this philosophical position descriptive relativists 
take no stand on whether beliefs about human behaviour within a particular 
cultural context are valid or not.  Normative relativism, on the other hand, is 
based on the assumption that each culture‟s beliefs are right within that 
culture. Thus those operating from the normative relativistic school of thought 
believe that it is impossible to validly judge another culture‟s beliefs and 
attitudes from outside of that culture. “Ultimately, worldview, cultural context 
and subsequent behaviours are appreciated and recognised in their own right” 
(p. 36). Thus in HIV vaccine trials those stakeholders holding a normative or a 
descriptive relativist position may argue that husbands should consent for their 
wives if it is culturally sanctioned to do so or if  his or her moral beliefs allow 






1.3.3.4.3. Intentionalism and informed consent:  
 
Intentionalism, often linked with realism, espouses the idea that there is 
always a mindfulness of and realization that some aspects of reality exist. 
Persons adhering to the intentionalist school of ethics believe that “the idea of 
morality is purposive and specific to a person‟s intent and/or motives” (p. 36). 
Those subscribing to Intentionalism are likely to be concerned about the 
motivation behind their clients‟ decisions and behaviour. It is likely, therefore, 
that the stakeholders of HIV vaccine trials who use an intentionalistic ethical 
outlook will consider the motivation behind participant‟s consent to 
participate in trials as imperative. 
 
Clearly when different stakeholders of HIV vaccine trials hold different 
underlying philosophical positions about informed consent conflict may arise 
at different levels of the informed consent process. While intentionalist are 
likely to be concerned about what motivates participants to consent, relativists 
may be more concerned about the cultural norms and personal beliefs 
regarding who gives consent, while absolutists may insist that the same 
universal informed consent  procedures apply universally. 
 
There is considerable debate in the literature that reflects these philosophical 
positions. Much of the debate centers on whether ethical principles are 
universal or relative, since morals are social constructions with ethical 
standards varying from culture to culture (Slack, Lindegger, Vardas, Richter, 
Strode & Wassenaar, 2000). Slack et al. (2000), (taking an absolutist‟s 
approach) argue that since ethical standards were propounded to restrain 
biological-medical research in the first place, where ever it occurs, these 
principles are specific to the activity and not the setting and thus should be 
applied worldwide. Other writers, including Mkhize (2006) and Shapiro & 
Stein (2004), (adopting a relativist position) propose that there must be 
sensitivity towards local cultural and ethical expectations. Benatar (2004) 
argues that the place of ethical universalism is at the abstract and conceptual 
levels, and then there is the need to seek reasoned ways of specifying how 
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abstract principles are applied at the local level. In doing so he advocates 
taking the position of reasoned contextual universalism, which allows for the 
rational application of universal approaches within local contexts. Achieving 
such middle ground avoids the abstraction that is blind to context while also 
avoiding the perils of moral relativism.  
 
1.3.3.5. Cultural sensitivity and informed consent: 
 
The notion of cultural sensitivity questions the substantive ethical standard of 
autonomy in informed consent, particularly in terms of first person consent. 
Cultural sensitivity in informed consent rests on the claim that the principle of 
informed consent, founded on the right to personal autonomy and self-
determination, is rooted in a particular notion of personhood, synonymous 
with the individualism of so-called western culture (Lindegger et al., 2006). 
Such notions of personhood are not universally valid since collectivist notions 
of personhood are the norm in eastern and African cultural contexts (ibid).  
Mkhize (2006), for example, argues that “concepts of autonomy based in 
western ethics often compete with local ethical systems” (p.27) with the result 
that attempts to implement first-person informed consent have met with 
problems in societies with a predominantly communitarian conception of self. 
For example, the threshold elements, information elements and consent 
elements, suggested by Beauchamp and Childress (2004) may have particular 
procedural difficulties when applied to a population who hold a 
communitarian worldview. These difficulties may arise when seeking 
individual consent in a society that values community decision making, for 
example. In general these procedural difficulties are likely to have 
implications for the informed consent process in research in Africa in general 







1.3.3.6. Moral theories that underscore informed consent: 
 
Moodley (2006) points out that 2000 years of moral debate, starting with the 
ancient Greeks, have produced secular moral theories that are still widely used 
and debated today in the context of biomedical practice and research. Three 
major moral theories that have dominated the debate include virtue ethics, 
consequentialism and deontology. Virtue ethics is the moral theory that 
concentrates on the character traits and virtues that persons should possess in 
order to do good, supporting the view that in order to do good one has to be 
good (Moodley, 2006). Hence, the good doctor or researcher should possess 
characteristics or virtues such as compassion, integrity, discernment and 
trustworthiness. Consequentialism is a theory based on the premise that 
consequences of actions define their morality so that the right action is the one 
that produces the greatest happiness for the greatest number of people (ibid). 
Deontology is a rule based morality that emphasizes a moral duty and moral 
rules, such as, „always be honest with your patient or research participant‟ 
(ibid).  
 
A brief description will follow to orientate the reader to some of the main 
tenets of these moral theories and how they may impact on informed consent 
in HIV vaccine trials.  
 
1.3.3.6.1. Virtue Ethics and informed consent: 
 
Virtue ethics is currently one of three major approaches in normative ethics 
and can be identified by its emphasis on the virtues, or moral character, in 
contrast to an approach that emphasizes the consequences of actions 
(consequentialism) or that which emphasizes duties or rules (deontology) 
(Hursthouse, 2007). Virtue, founded by Plato and more particularly Aristotle, 
persisted as the dominant approach in Western moral philosophy until the 
Enlightenment when it took a momentary eclipse (ibid). It re-emerged in the 
late 1950‟s at the increasing dissatisfaction with the prevailing forms of 
deontology and utilitarianism at the time (ibid). These theories paid little 
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attention to the virtues themselves, motives and moral character, moral 
education, moral wisdom or discernment, friendship and family relationships, 
a deep concept of happiness, the role of emotions in our moral life and the 
important questions of what sort of person one should be and how one should 
live (ibid). It is important to realize that virtues such as honesty and generosity 
are not just a tendency to do what is honest or generous. They are concerned 
with emotions and emotional reactions, choices, values, desires, perceptions, 
attitudes, interests, expectations and sensibilities (ibid). Thus to possess a 
virtue is to be a certain type of person with a certain complex mindset.  
 
In terms of getting informed consent from an HIV vaccine trial participant, a 
virtuous agent would not hesitate to tell the participant the truth about the real 
risks of participation, not just because it is part of the informed consent 
protocol, but because there is real value in truth telling that reflects honesty. 
Steenivasan (2002) argues that given that virtue is such a multi-track 
disposition, one must know the agent‟s reasons for doing something before 
considering him as a virtuous moral agent. The concept of virtue is the 
concept of something that makes its possessor good, in that a virtuous person 
is morally good, excellent or an admirable person who acts and feels rightly as 
they should (ibid). However, to possess fully such a disposition is to possess 
full and perfect virtue, which is rare (Athanassoulis, 2000, in Hursthouse, 
2007) and an idealistic expectation to have, for example, of stake holders of 
HIV vaccine trials.  
 
Opponents of virtue ethics commonly assert that someone‟s compassion might 
lead them to act wrongly, to tell a lie they should not have told, for example 
(Steenivasan, 2002). Thus if virtuosity becomes a criteria for choosing 
stakeholders for trials, one must consider that, in their desire to allow a 
participant to enter a trial to get access to the benefits of the trial whilst being 
aware that they do not fully understand the risks of the trial, a virtuous agent‟s 
compassion might lead him or her to act wrongly. Thus it would appear that 
generosity and compassion, despite being virtues, are sometimes faults and 
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morally good people may be lead by what makes them morally good to act 
wrongly (Hursthouse, 2007). 
 
1.3.3.6.2. Consequentialism and informed consent: 
 
A moral theory is a form of consequentialism if and only if it assesses acts 
and/or character traits, practices and institutions solely in terms of the 
goodness of the consequences (Hooker, 2007). Consequentialists can and do 
differ widely in terms of specifying the good, with some specifying the good 
in terms of pleasure, happiness, desire satisfaction, or welfare, while others 
merely add up each person‟s share of the Good to achieve the Good‟s 
maximization (Alexander & Moore, 2007).   
 
Historically, utilitarianism has been the best known form of consequentialism 
whereby acts and/or character traits, practices and institutions are assessed in 
terms of their overall net benefit which is often referred to as wellbeing or 
welfare (Hooker, 2007). Overall welfare is calculated by counting a benefit or 
harm to any one individual the same as the same size benefit or harm to any 
other individual, and then adding all the benefits and harms together to reach 
an aggregate sum (ibid).   
 
There is considerable dispute among consequentialists regarding what the best 
account of welfare is, however. Classical utilitarians viewed benefit and harm 
to be purely a matter of pleasure and pain so that how well a person‟s life goes 
depends entirely on his or her pleasure minus pain (Parfit, 1984; Streumer, 
2003). Hooker (2007) argues that a criticism often levelled against such a 
hedonistic approach to what constitutes welfare is that many people care very 
strongly about things over and beyond their hedonistic instrumental value. For 
example, many people want to know the truth about various matters even if it 
does not increase their pleasure.  
 
What is controversial is whether the fulfilment of one‟s desires constitutes a 
benefit or harm to that person regardless of how the person feels about it. 
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Where hedonistic theories argue that only effects on felt satisfaction or felt 
frustration matter the desire-fulfilment theory of welfare holds that the 
fulfilment of any desire of the agent constitutes a benefit to the agent, even if 
the agent never knows that a desire has been fulfilled and even if the agent 
derives no pleasure from it.  Thus “what constitutes a benefit is wider than 
merely pleasure” (p.3) so that a much broader range of benefits and harms can 
be included in a utilitarian analysis of overall welfare. How does this apply to 
research? Using the desire-fulfilment theory of welfare, it can be argued that 
the practice of obtaining informed consent from all research participants is 
contingent upon whether such a practice will benefit the overall welfare of the 
research community involved. Thus in terms of HIV vaccine trials, 
stakeholders who prescribe to this ethical framework, could argue that if the 
informed consent process is too arduous, and threatens to delay or prevent the 
implementation of trials, which are of obvious benefit to the greater good, 
then it should be omitted or at least modified. 
 
Consequentialism is often criticized for what it seemingly permits or requires 
in producing greater benefits for others. Consequences alone can thus 
conceivably justify any kind of act, no matter how harmful it is to some 
(Alexander & Moore, 2007). For example, stakeholders holding a 
consequentialist viewpoint could argue that community members who fit the 
prescribed criteria for participation in HIV vaccine trials could be seen as 
having an obligation to participate in trials for the benefit of society as a 
whole. To insist on such an obligation, however, the consequentialist would 
have to prove that HIV vaccines do have overriding benefits to society, a 
difficult task, considering that the nature of HIV vaccine research is 
investigative, and the efficacy of vaccines unproven.  
 
1.3.3.6.3. Deontology and informed consent: 
 
The word deontology derives from the Greek words for duty (deon) and 
science of (logos) (Alexander & Moore, 2007). In contemporary moral 
philosophy deontology is a normative theory regarding which choices are 
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morally required, forbidden or permitted, that falls within the domain of moral 
theories that guide and assess our choices of what we ought to do in contrast 
to virtue theories that guide and assess what kind of person, in terms of 
character traits, we should be (ibid). Deontological theories (of which 
Immanuel Kant is a well known proponent) stand in contrast to 
consequentialist theories in that they judge the morality of choices by criteria 
independent of the states of affairs those choices bring about so that no matter 
how morally good their consequences, some choices are morally forbidden 
(ibid). For deontologists what makes a choice right is its conformity with a 
moral norm (ibid). The Right thus has priority over the benefit, and an act that 
is not in accord with the Right may not be undertaken no matter the benefit 
that it may produce (ibid).  
 
Alexander and Moore (2007) differentiate between agent-centred, patient-
centred and contractarian deontological theories and their different ethical 
applications. These ethical theoretical arguments are beyond the scope of this 
thesis and will not be considered at this point. With regards to the doctrine of 
informed consent, however, a deontological perspective may concern itself 
with the basic ethico-legal principles put in place to protect the patient‟s right 
to dignity by ensuring that the participant‟s informed preferences are brought 
into the health care practitioner‟s plans (Dhai, 2008).  Thus those stakeholders 
holding a deontological viewpoint to the informed consent process in HIV 
vaccine trials are likely to be particularly concerned more with protecting the 
substantive element of autonomy and legal procedures put in place to protect 
it. A valid consent process that includes, for example, disclosure, 
understanding, capacity and voluntariness (Dhai, 2008) is likely to be of 
paramount importance.    
 
These ethical theoretical positions may underscore the views stakeholders 





1.3.3.7. Issues related to competency to consent to research: 
 
The relevance of a person‟s mental capacity to the adequacy of his or her 
consent to research was first formally recognized in the Nuremberg Code and 
later the Declaration of Helsinki (Appelbaum, Loren & Roth, 1982). The 
fundamental requirement of informed consent was that every person taking 
part in research must have legal capacity to give consent (ibid). The standards 
of competency to consent have been proposed to include four groups of 
standards by which an individual‟s capacity to consent can be assessed (ibid).  
Research participants must demonstrate that they can communicate a choice, 
have factual understanding of the issues, be able to rationally manipulate the 
information in the decision-making process, and have an appreciation of the 
nature of the situation (ibid). Beauchamp and Childress (2004) have described 
competence in relation to autonomy. Simply put, a person is deemed 
competent to make a decision to participate in research if he or she has the 
capacity to understand the material information, make a judgment about that 
information in light of his or her values, to intend a certain outcome, and to 
freely communicate his or her wishes to the research investigators.  
 
Many writers have launched cultural and anthropological arguments objecting 
to this formalistic requirement of legal competency to consent to research. 
Writers have often appealed to difficulties in communication and 
comprehension, from differences in language, non-scientific conceptions of 
health and illness, or from poor education (IJsselmuiden & Faden, 1992) to 
urge researchers to adapt the information ordinarily used in the process of 
obtaining informed consent to local concepts of disease and health (Ekunwe & 
Kessel, 1984).  
 
Implicit in the arguments based on the problems of incompetence, is the view 
that it is time consuming and difficult to obtain informed consent from 
subjects in developing countries (IJsselmuiden & Faden, 1992). For instance, 
commenting on a case study done to ascertain the distribution of hydatid 
disease, Ekunwe argues that it is permissible for a physician to obtain what is 
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best described as „uninformed consent‟ from research subjects who are 
“among the not so educated members of the population” (p. 23), particularly 
in most developing countries where the germ theory of disease causation is 
not yet accepted. Ekunwe states that if the research team “cannot convince 
them [research subjects] of the true etiology and pathology of the disease 
[they] should not waste their time” (p.23). He justifies this by claiming that 
the researcher is informed on the patient‟s behalf as he knows that: (1) the 
procedure is essential to the health care policy decision [to carry out the 
research] and (2) the risks involved are tiny and no more than the risk of 
having regular clinical tests. Although this may be true for studies involving 
minor procedures such as blood tests, IJsselmuiden and Faden (1992) argue it 
certainly cannot be said of investigations involving much higher risks to 
participants [such as the potential risk of seroconversion in HIV vaccine 
trials].  
 
1.3.3.8. Children and Informed consent: 
 
UNAIDS estimates that of the 4.9 million new HIV infections in 2004, 640 
000 occurred in children less than 15 years of age (Jaspan, Gray, Robinson, 
Coovadia & Bekker, 2005). Jaspan et al., (2005) argue that this 
epidemiological fact makes it clear that both children and adolescents are at 
the highest risk of HIV infection and to have any hope of successful epidemic 
control it is imperative that an HIV vaccine target this group. However, 
involving adolescents in the participation of HIV vaccine trials raises a 
number of ethical and legal issues (Brindley-Richards, 2006). 
 
There are inconsistencies in the South African law regarding the age at which 
capacity to consent can be presumed (Brindley-Richards, 2006). The South 
African Constitution states that no person shall be subjected to 
experimentation without informed consent and when persons under the age of 
18 years are to be involved in research proxy consent from a parent or legal 
guardian as well as assent from the child must be obtained (Medical Research 
Council, n.d.). According to the Medical Research Council (n.d.) however, 
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any person over the age of 14 years is competent to consent without the 
assistance of a parent or guardian to any medical treatment but not to research. 
Those who have formulated guidelines and regulations have struggled with 
how to promote the best interests of children as a group through research 
whilst protecting the rights and welfare of individual research subjects (Slack 
& Kruger, 2005). For example, Book 1 of the Medical research Council 
guidelines (2001) has more restrictive provisions on research involving 
research with children than other South African guidelines that, Slack and 
Kruger argue, rest on a number of conceptually confusing provisions such as 
the classification of research as „therapeutic‟ or „non therapeutic‟ (p. 269).  
 
HIV vaccine trials require informed consent at a number of different stages. 
The first stage consists of screening candidates for eligibility to participate 
involving an assessment of the individual‟s risk-taking behaviour and their 
ability to give consent (Medical Research Council, n.d.). Although one thinks 
of respect for autonomy as applying only to adults the National Commission 
for the Protection of Human Subjects in Biomedical Research recognises that 
individuals do not suddenly develop the capacity to make their own decisions 
at the age of 18 years but rather their decision making capacity develops over 
time, with many children being able to make their own decisions before they 
reach the legal age of adulthood (American Academy of Paediatrics 
Committee on bioethics, 1995, in Wendler & Shah, 2003). The implication is 
that the threshold for consent should be fixed at the age when (most) children 
become capable of making their own research decisions.  
Wendler and Shah (2003) argue that the threshold for children to consent to 
research should be fixed at the age of 14 years of age and that a dissent 
requirement should be adopted for all children in the context of non-beneficial 
research. However, most commentaries regard the assent requirement (defined 
as positive agreement) as an important protection for children (Kodish, 2003) 




In the US, federal regulations only specify that when determining which 
children are capable of consent one should take into account the children‟s 
ages, maturity and psychological state (Wendler & Shah, 2003). The question 
is which aspects of children‟s age, maturity and psychological state should 
investigators take into account when determining whether they are able to 
consent (Brindley-Richards, 2006)? Is the ability to communicate a decision 
sufficient or must children have full understanding of the purpose of the 
research, its risks and the alternatives? Or should investigators only rely on a 
general age threshold, and if so, which one (Wendler & Shah, 2003)? 
Wendler and Shah (2003) suggest that in order to determine which children 
are capable of consent it may be helpful to identify the rationale behind the 
assent requirement. They point out that the National Commission for the 
Protection of Human Subjects in Biomedical Research (1977) states that the 
consideration of children‟s assent to non beneficial research begins with the 
respect for subject‟s autonomy, which implies that “individuals who can 
understand and shape their lives should be allowed to decide whether to enrol 
in research based on their own conception of a flourishing life” (Wendler & 
Shah, 2003, p.2).  
Berg (2001, in Wendler & Shah, 2003) argues that to make an autonomous 
decision as to whether to enrol in research, potential subjects must be able to 
understand the study in question and their own medical and personal 
situations, and make a voluntary decision to participate on this basis. In 
addition, Wendler and Shah (2003) propose that potential subjects must 
appreciate how the elements of informed consent pertain to their own 
circumstances. This involves not only an understanding that a study poses 
certain risks or injury but an appreciation of how this risk is relevant to their 
circumstances. Wendler and Shah (2003) argue that the most abstract element 
of informed consent is the purpose of research. As non-beneficial research is 
intended to develop generalizable knowledge that might help others, the age at 
which children understand and appreciate these more abstract elements of 
informed consent provides an approximation of the age at which they can 
make their own research decisions. However, as Wendler and Shah (2003) 
25 
 
point out, understanding and appreciating the purpose of non-beneficial 
research does not require that the potential subjects are motivated to help 
others. An individual can understand fully that a study is intended to help 
others but not care to help them in that way. 
To demonstrate this, Wendler and Shah (2003) suggest one looks at it from 
the perspective of incapacity. Children who do not understand the concept of 
altruism cannot decide for themselves whether helping others by enrolling in 
non-beneficial research would further their conception of a flourishing life. 
They cannot decide whether the moral reasons for helping outweigh the risks 
of the research. Therefore the autonomy rationale suggests the consent 
threshold should be fixed when most children develop the concept of altruism. 
Ausubel (1977) have proposed that because adolescents‟ thinking is more 
flexible and abstract than younger children, they can accommodate a variety 
of complicating factors in deciding moral issues. However, Mussen, Conger, 
Kagan and Huston (1990) argue that given the complexity of modern society, 
in which numerous factors have to be weighed up against each other, many 
adolescents struggle to be consistent in applying their moral principles. 
Further, adolescence is often characterised by conflict, mainly with parents, 
about moral issues, attributed to the way in which they seek certainty about 
their identity. Bester (1992, in Gouws, Kruger & Burger, 2000) argues that 
age itself cannot cause a change in moral judgements, but rather it is a change 
in age accompanied by a change in cognitive, affective and social 
development that affects moral development. Factors influencing adolescent 
moral development include parental warmth and trust, the frequency and 
intensity of parent-adolescent interactions, the type of discipline adolescents 
receive, peer group influence, mass-media exposure, schooling and cultural 
factors within their community.  
1.3.3.9. Notions of personhood and informed consent:  
 
IJsselmuiden and Faden (1992) argue that the anthropological  literature on 
Africa is often represented as indicating that it is “typical of African culture 
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that the person perceives him or herself as an extension of the family and as 
an intermediary between ancestors and future generations rather than an 
individual person in his or her own right” (p.831) and, that in terms of social 
structures, that authority is located in the leader of a village or tribe and in the 
head of the household who is usually a man. Responses to these observations 
argue that insistence on first-person informed consent in group oriented 
cultures is a form of medical ethical imperialism that is morally unacceptable 
(Barry, 1982; Taylor, 1979; Willett, Kilama & Kihamia, 1979).  
 
Lindegger et al. (2006) point out that behavioural researchers in this area 
caution against the risk of assuming cultural homogeneity, that is, “the 
assumption that every person of a particular ethnic, religious, or language 
group or living in a circumscribed geographic region shares the cultural 
beliefs, values, and identity of that group” (p.722). IJsselmuiden and Faden 
(1992) have also argued that there is no single African culture, with more than 
900 different contemporary or historical ethnic and cultural groups having 
been described in Africa (Price, 1989).  
 
Spiro (2000, in Lindegger et al., 2006), based on a review of the 
anthropological research on cultural variations in self-construction, argues that 
an important distinction needs to be drawn between manifestations of 
personhood at a group or collective level and individual experiences of 
personhood.  He warns that much of the research providing apparent evidence 
for differences in notions of selfhood between westerners and non-westerners 
is drawn from expressions of personhood seen in symbols, beliefs, and values 
of groups of people at a collective level which may not necessarily exist at the 
level of individual experience of selfhood. Gasa‟s (1999) research on 
indigenous understandings of informed consent in rural KwaZulu-Natal, for 
example, found that some African women were strongly in favour of 
individual consent for participation in clinical trials, despite their membership 





Although studies of cross-cultural comparisons in construction of self 
(Lindegger, 2002; Hart & Lindegger, 2002), found “evidence of differences in 
self-construction, with more individual constructs of self in English-speaking 
white participants and more collective constructs in isiZulu-speaking black 
participants” (p. 722), their studies have also revealed marked intra-group and 
even intra-individual variation in notions of self, as a function of the contexts 
of time and space. These and other studies challenge the assumption that 
Western and non-Western cultures are clearly dichotomized in their notions of 
personhood, and suggest it would be very risky to assume the irrelevance of 
informed consent, especially first-person consent, in some communities 
(Lindegger et al.,  2006).  
 
1.3.4. Considerations related to the procedural element of informed consent: 
 
1.3.4.1. Procedures involved in informed consent:  
 
Lindegger and Richter (2000) highlight point 12 of the most recent 
prepublication version of the UNAIDS guidelines for HIV vaccine research, 
which states that “Independent and informed consent based on complete, 
accurate and appropriately conveyed and understood information should be 
obtained from each individual while being screened for eligibility for 
participation in an HIV preventative vaccine trial and before she or he is 
enrolled in the trial. Efforts should be taken to ensure throughout the trial that 
participants continue to understand and to participate freely as the trial 
progresses. Informed consent, with pre and post test counseling, should also 
be obtained for any testing for HIV status conducted before, during and after 
the research” (p. 313).  
 
In addition “A process of consultation between community representatives, 
researchers, sponsor(s) and regulatory bodies should be used to design an 
effective informed consent strategy and process. Issues such as illiteracy, 
language, and cultural barriers, as well as diminished personal autonomy 
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should be addressed in this consultative process” (p. 313). “Three guidance 
points on informed consent are also included in the Medical Research Council 
(2003) guidelines. Guidance Point 12 requires ongoing informed consent for 
each stage of participation in the research. Guidance Point 13 requires that 
special measures be taken for people who might have limited ability to 
provide informed consent. Guidance Point 15 requires ongoing monitoring of 
the informed consent process” (Lindegger et al., 2006, p. 716). 
  
With regards to what particular information participants will need to be 
provided with the CIOMS guidelines (cited in Lindegger & Richter, 2000) 
prescribe that prospective clients must be informed:  
1. that they have been selected for participation because they are at high risk 
of HIV infection; 
2. that they will receive advice and access to means to reduce their risk (such 
as condoms), although some of the participants in the trial may nonetheless 
become infected as a result of their high risk status; 
3. that only some of the participants will receive a vaccine, while others will 
receive a placebo;  
4. that the effectiveness of the vaccine to be tested in preventing HIV infection 
or AIDS disease is not known; 
5. that only some of the specific risks of physical, social and psychological 
harm are currently known or anticipated – such as testing HIV positive as a 
result of the vaccine and being labelled as being HIV positive, with possible 
discrimination, by communities as a result, and; 
6. of the nature and duration of the care and treatment that is available to 
them, should they become infected with HIV during the trial. 
 
As Lindegger and Richter (2000) argue, informed consent is a complex and 
some what idealised process and that these formalistic requirements are, in 
many ways, almost impossible to meet, “a reality that necessitates a careful 
analysis of the aims of informed consent as an ethical rather than formalistic 
condition” (p. 313). Alexander and Moore (2007), on the other hand, argue 
that just because the application of ethical practice (procedural elements) may 
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be difficult to achieve does not mean that the ethical principle (substantive 
element) needs to be revised but rather that those instituting procedures should 
try harder to apply the principle. In other words, the substantive element of 
Informed consent should not be held hostage, to the procedural difficulties 
researchers may face in its implementation.  
 
The main issues addressed in the literature regarding the difficulties of 
implementing informed consent in HIV vaccines trials concern the 
confrontation between culture and ethics, ensuring voluntary participation, 
evaluating the competence of participants and whether children can consent, 
assessing participant understanding, how and what information to disclose, 
and confronting legal issues.  The next section discusses these contentious 
issues.   
 
1.3.4.2. The practice of cultural sensitivity in informed consent: 
 
Lindegger et al. (2006) point out that one of the most widely debated aspects 
of informed consent centers on the practice of cultural sensitivity in informed 
consent. Although cultural sensitivity is a substantive issue in informed 
consent the implementation of culturally sensitive informed consent has 
procedural implications. Bayer (2000) suggests that there are three possible 
ways of understanding cultural sensitivity: semantic, instrumental, and 
principled. First, semantic understanding refers to the use of appropriate and 
understandable language, when providing participants with information about 
trial participation. Second, instrumental meaning refers to understanding how 
social and cultural context might affect participation in a trial, as, for example, 
in obtaining the permission of traditional leaders to commence a trial 
(Moodley, 2002). Third, the principled meaning refers to the notion that 
research ethics should not challenge or undermine cultural norms.  
 
Suggestions have been made to modify informed consent requirements to suit 
the cultural context wherein trials take place. IJsselmuiden and Faden (1992) 
propose that to modify informed consent requirements the complex 
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motivation behind decisions to conduct research in developing countries must 
be taken into account. Some reasons for carrying out studies in Africa are 
questionable, they argue, and include factors such as lower costs; lower risks 
of litigation; less stringent ethical review; the availability of populations 
prepared to cooperate with almost any study that appears to be curative in 
nature; anticipated underreporting of side effects because of lower consumer 
awareness, the desire for personal advancement and, the desire to create new 
markets for pharmaceutical agents and other products. The existence of such 
an array of reasons to carry out research in Africa that are “generally 
antithetical to the interests of research subjects” (p.833) provides justification 
for being suspicious of any suggestions to replace or modify the requirements 
for first-person informed consent. 
 
Some writers have suggested that in addition to, or even instead of, first-
person informed consent researchers should obtain consent on behalf of 
otherwise competent adults from a trusted village leader (Cash, 2006; 
Moodley, 2002).  In addition to Bayer‟s (2002) argument that in principle this 
would violate the substantive element of informed consent, IJsselmuiden and 
Faden (1992) propose a number of practical reasons why this may not be 
feasible. They propose that besides the dwindling numbers of such persons, as 
a result of urbanization and development, there are serious problems in 
identifying who they are and in assessing whether or not they are genuinely 
trusted by the community. With reference to consent given by the heads of 
households on behalf of women, for example, migrant labour often takes the 
male heads of households away to urban areas for the greater part of the year 
whilst at the same time women‟s educational status and the number of 
households headed by women are increasing, particularly as a result of the 
AIDS epidemic (ibid).  
 
Furthermore there is increasing demand for the end of discriminatory practices 
against women challenging the justification of asking heads of households for 
consent on behalf of competent adults, a practice that would be morally 
incomprehensible in the West. In addition, this is “certainly out of step with 
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the movement of many African countries toward structural changes to 
enhance the emancipation of women” (p. 831) most exemplified by the 
Woman‟s League of the African National Congress in South Africa 
(IJsselmuiden and Faden, 1992).  
 
IJsselmuiden and Faden (1992) argue that appeals to cultural sensitivity are no 
substitute for careful moral analysis, and that there are no convincing 
arguments for a general policy of dispensing with, or substantially modifying, 
the researcher‟s obligation to obtain first-person informed consent in 
biomedical research in Africa. They substantiate their view by claiming that 
those who defend such a policy have relied on limited and often dated 
anthropological literature that does not reflect the rapid cultural changes 
brought about by colonialism and independence, warfare, and urbanization, 
together with their tendency to confuse appeals to problems of competence 
and communication as well as their exaggerated sense of the role of 
biomedical research in solving Africa‟s pressing health problems.  
 
What is clear is that there is a need for great caution in making broad claims 
about the non-applicability of informed consent (including first-person 
consent) in various cultural contexts (Lindegger et al., 2006). However, the 
Medical Research Council (2003) and UNAIDS (2000) suggest that informed 
consent procedures should be implemented in a manner that respects cultural 
norms, such as inviting participants to involve important others in the consent 
process, and asking permission of legitimate leaders to enter a community.  
 
1.3.4.3. Issues regarding the voluntariness of informed consent:  
 
Lindegger and Richter (2000) highlight a number of contentious issues in 
informed consent that need consideration when designing HIV vaccine trials. 
They argue that one of the several issues that can potentially confuse informed 
consent as an expression of individual autonomy is that of social desirability. 
Their research has demonstrated the tendency for volunteers in trials to 
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behave and respond according to what they surmise to be socially acceptable 
norms for the situation. This includes trying to create a favourable impression 
to win the favour of researchers, and /or, fearing reprisals for giving an 
unfavourable impression, particularly when researchers are viewed by 
volunteers as being in a powerful position. Further more participants‟ 
decisions may be influenced by the amount and types of rewards offered for 
their participation. An issue that remains controversial is the issue of what 
type of incentive and how much incentive to offer participants to partake in 
HIV vaccine trials. It is generally accepted that if incentives are too great they 
may act as undue inducements enticing participants to take part in order to get 
the benefit. 
 
1.3.4.4. Information Disclosure: 
 
Information is a prerequisite for active involvement in decision making about 
research participation (Forde & Vandvik, 2005). According to the Declaration 
of Helsinki, patients who take part in clinical trials must be “adequately 
informed about the trial‟s aims, methods, anticipated benefits and potential 
hazards of the study and any discomfort it may entail” (Recommendation 9, 
p.38). Despite this Forde and Vandvik (2005) argue that issues relating to 
patient information and communication have generally been given low 
priority. Lindegger et al., (2006), however, argue that most ethical codes 
provide specific guidance on what information must be disclosed to potential 
participants. In addition to those suggested above they include information 
regarding the right to withdraw. However, they also argue that, “if this 
information is to enable potential participants to make meaningful personal 
decisions, it needs to be relevant to their personal interests and circumstances, 
and provided in a way that makes sense to them” (p. 719).  
 
There has been much controversy in the literature about information 
disclosure to research participants (Lindegger & Richter, 2000; Harper, 2007; 
Moodley, 2002). Two aspects, concerning the quantity and content of 




First, is the question of how much information should be provided to potential 
trial participants? Faden and Beauchamp (1986) make a distinction between 
legal and ethical versions of informed consent. To satisfy the legal 
requirement for informed consent all information required by ethical codes 
should be disclosed. However, as Lindegger et al. (2006) argue, the provision 
of excess or inappropriate information (especially technical) may 
unnecessarily complicate decision making, burden the participants, or increase 
their anxiety, which may not facilitate a good decision-making process and 
therefore may not be informed consent in the full ethical sense. This may 
especially be the case where there is a lack of appropriate language for 
scientific terms in certain indigenous languages (Moodley, 2002). Lindegger 
and Van Loon‟s (2004) recent study that involved intensive interviews with 
clinical trial researchers and staff about informed consent revealed that 
potential participants often find long forms difficult to understand. “Even 
though forms are translated into local languages, interviewees reported that 
forms should be written in „street language‟ to improve understanding” (p. 
720). In addition, it was found that trial stakeholders often find themselves in 
a double-bind situation regarding information disclosure, when community-
based groups request full information disclosure in the interests of 
transparency and trust-building, but, on the other hand, are concerned that 
excess information will impede decision making.  
 
Second, is the question of who should decide on what information to provide, 
and who should provide the information? Lindegger et al. (2006) suggest that, 
whereas, researchers may believe they are well placed to decide what 
information to give, based on their technical expertise, community advisory 
boards might also claim that they are better placed as advocates for the 
community‟s interests. Veatch (1995, in Lindegger et al., 2006) has 
recommended the principle of „value-pairing‟ in deciding who should best 
provide this information. “This principle suggests that people who share the 
core cultural, social, religious, and other values might be best placed to decide 
what information should be provided, and to transmit it” (p. 720). However, it 
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is possible that in small communities those who share similar values may be 
known to participants, threatening confidentiality (Lindegger et al., 2006). In 
addition, Lindegger and Van Loon (2004) found that trial counselors 
obtaining informed consent often feel a heavy burden of ensuring 
understanding by participants.  
 
The role of the media in disseminating information about HIV /AIDS has been 
well documented. In relation to informed consent Hanefeld (in Hanefeld, 
Coates & Kruger, 2005) describes the media‟s role as information provision 
about modes of transmission, prevention, treatment and care. The potential of 
the media to influence behaviour, effect social change, challenge sexual norms 
and attitudes and influence policy (ibid) has also been highlighted. Cullinan 
(2001) has brought to focus a number of media violations in the reporting of 
HIV/AIDS, however. The most troubling violation pertains to the violation of 
the privacy of ordinary people living with HIV. Guidelines set out for media 
reporting on HIV/AIDS include, amongst many, avoiding sensational 
reporting, avoiding stereotyping and discrimination and using sensitive, non-
discriminatory, simple and understandable language (Swanepoel, Fourie & 
Froneman, 2005).  
 
The minimum standard of what participants of HIV vaccine trials should be 
informed of, and what they should understand, is described by Lindegger and 
Richter (2000) to include: the rationale for the study (such as the reason for 
developing an HIV vaccine), technical issues (of the nature of the products), 
technical consequences (possible side effects), unknown outcomes (that there 
is no guarantee that HIV vaccines will offer any protection against HIV 
infection), methodological issues (placebo or randomization), practical aspects 
involved in personal participation (e.g., the kinds of procedures and tests that 
participants will have to undergo), the costs and benefits of participation in the 
study (e.g., the reduced benefits from future vaccines or access to treatment), 
and the personal implications of participation in the study (e.g., discovery of 




1.3.4.5. Promoting and assessing understanding: 
  
Ferguson (2002) argues that a patient‟s consent to participate in a clinical trial 
can only be regarded as morally acceptable if he or she is competent and a 
genuine volunteer. Not only does this imply that potential participants be 
provided with adequate information on which to make a decision, but later 
requirements of informed consent insisted that they must also be able to 
understand the information. With regards to understanding of disclosed 
information Lindegger et al. (2006) suggest two ways in which behavioural 
issues become important. First, in finding what the most appropriate way of 
improving understanding is, even though most vaccine sites have elaborate 
preparatory processes for potential participants, mainly in the form of vaccine 
discussion groups. Second, what is the best way to „test‟ understanding? To 
determine whether subjects have understood the information presented to 
them, Kessel (in Ekunwe & Kessel, 1984) suggests that the best alternative is 
to provide an opportunity for subjects to ask questions even though they may 
have difficulty in framing them. This may require the researcher to develop a 
setting in which subjects are encouraged to explore the nature of the study and 
its potential risks and benefits and gives the researcher an opportunity to 
determine the meaning that the subject gives to disease, such as HIV/AIDS for 
example, and his or her own understanding of the risks and benefits to be 
derived from the study. 
 
Ferguson (2002) argues that self reports on understanding may not be reliable. 
Although the results from his study found that in general patients felt that they 
were given appropriate amounts of information and reported a reasonable 
level of understanding these findings are not synonymous with a finding that 
patients are capable of assimilating the information they are given. “Patients 
may feel they have a reasonable grasp of a concept, but if this were to be 
tested it might not in fact be correct” (Ferguson, 2002, p.48).  
 
Lindegger et al. (2006) point out that it has become common practice for HIV 
vaccine trial sites to assess understanding over and above self-reported 
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understanding, which may be heavily influenced by social desirability 
processes (Lindegger & Richter, 2000, in Lindegger et al., 2006). Even though 
the most common way to test understanding at sites appears to be forced-
choice or multiple-choice checklists of key concepts (Lindegger et al., 2006) 
which are very cost-effective, they may be measures of short-term recall of 
technical information rather than measures of personal understanding 
(Lindegger & Richter, 2000). It is possible that, despite adequate checklist 
scores, participants may not have understood trial information in terms of the 
personal implications (Lindegger et al., 2006). Flory and Emanuel (2004) 
argue that repeated use of checklists may measure well-learnt responses that 
do not reflect real understanding, and suggest that these binary (right/wrong) 
approaches may run the risk of cultural insensitivity. 
 
Several studies have found that the information provided to patients is too 
technical for the lay person to understand, or is pitched at a reading age that is 
too advanced for many participants (Ferguson, 2002). Ingelfinger (1972) has 
agued that it would be impractical and probably unethical for investigators to 
present endless lists of all contingencies to research participants. Priestley, 
Campbell and Valentine (1992 in Ferguson, 2002) compared the readability of 
50 consent forms for clinical trials with ten top British daily newspapers using 
the Gunning Fog and Flescch-Kincaid indices. They found that the consent 
forms were significantly more difficult to read than newspaper editorials. 
Whilst Ferguson (2002) cites several studies that have subjected information 
leaflets to scrutiny (see Grossman, Piantadosi & Covahey, 1994; Meade & 
Howser, 1992; Tarnowsky, Allen & Mayhall,1990), with some studies asking 
potential trial participants to assess their information requirements in respect 
of hypothetical trials (see Corbett, Oldham & Lilford, 1996), only a few 
studies have asked patients who are actually participating in actual trials to 
assess the adequacy of the information they received about the trial. 
 
Results from a study done on Aborigines suggest that a one-off presentation of 
informed consent materials, even if designed specifically for Aboriginal 
people, is unlikely to produce the level of „„informed consent‟‟ that is legally 
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and ethically required by current guidelines for participants in research 
(Russell, Carapetis, Liddle, Edwards, Ruff & Devitt, 2005).  In comparable 
indigenous populations Russell et al. (2005) point out that it has been argued 
that morality and ethics are community rather than individual issues. “Our 
experience supports this view, and also that the current process of promoting 
individual autonomy over collective or consensual decision making may not 
reflect the ways in which decisions are made in some cultures” (p. 492 ).  
 
1.3.4.6. Legal Issues and Informed consent: 
 
Legally regulated informed consent has become the main modality for 
achieving patient autonomy within medical ethics and research (Harper, 
2007). Human rights questions have been raised most particularly in the 
context of HIV/AIDS, where affected people suffer extensive stigma and 
discrimination (Slack, et al., 2000). Thus promoting human rights protects the 
inherent dignity of persons affected by HIV/AIDS (ibid). Since much HIV 
vaccine development work will take place in under resourced communities 
where people are at high risk of HIV infection, human rights implications for 
participants and communities need careful consideration (ibid).  Slack et al. 
(2000) cite a number of physiological and psycho-social risks of participation 
in HIV vaccine trials that may impact participants, accentuating why informed 
consent is such a critical issue for HIV vaccine Trials vaccine trials. The fact 
that participants may be exposed to such severe potential risks, some of which 
are still unknown, justifies the need for further research into the process of 
informed consent and its implementation in HIV vaccine Trials vaccine trials. 
 
1.3.4.6.1. The South African Constitution and informed consent: 
 
In an attempt to protect research participants from being coerced into 
participation in HIV vaccine trials, which poses considerable potential risk to 
participants, Dhai (2008) points out that section 12 of the Bill of Rights, of the 
South African Constitution on freedom and security of persons, affirms that 
all individuals have the right to bodily and psychological integrity, ensuring 
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the right to security and control over their body. Dhai (2008) argues that 
although all patients and research subjects have the right to free choice and 
informed consent and refusal in the health care context every right has a 
corresponding responsibility. An important aspect of the informed consent 
process would be the need to highlight the importance of patients honouring 
their obligatory responsibilities as being part of the health practitioner-patient 
or researcher-participant relationship.  
 
1.3.4.7. Ethical guidelines on informed consent:  
 
A number of ethical guidelines have been produced both internationally and 
locally for the conduct of health research on human subjects. Section 72(6) of 
the National Health Act empowered the National Health Research Ethics 
Council (NHREC) to set up ethical guidelines to govern all health research in 
South Africa (Strode, Slack & Mushariwa, 2005). Other guidelines issued by 
the South African Medical Research Council, adapted from the UNAIDS 
(2000) Ethical considerations in HIV Preventive Vaccine Research, include 
the Guidelines on Ethics for Medical Research. HIV Preventive Vaccine 
Research (ibid).  In addition, the Medicine Control Council‟s HIV Vaccine 
Clinical Trials Group is also developing draft HIV/AIDS vaccine trial 
guidelines that include recommendations regarding the conduct of HIV 
vaccine trials.  
 
In common with most ethical guidelines for research the National Committee 
for Ethics in Social Research in Health (NCESSRH) (2003) guidelines 
stipulate a number of requirements for informed consent. Amongst others 
these guidelines require that consent for participation in research is voluntary 
and informed, be given both verbally and in writing, that participants are 
furnished with written information giving adequate details of the research in a 
manner and language that the participants know and understand and 
demonstrate an adequate amount of comprehension of this information, that 
participants are given anonymity and confidentiality, that they know they have 
the right not to participate and the right to withdraw from the research, that 
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consent is an on going process and that participants are given adequate 
protection from discriminatory practices. In addition where permission is 
obtained from community gatekeepers this consent must not be substituted for 
the need to take separate and full informed consent from participants. 
 
What challenges stakeholders anticipate in implementing these guidelines in 




Different notions of informed consent have been reflected in the literature. 
Whereas some refer to formal consent based on legal rules, others, taking a 
moral approach, refer to informed consent as a process of shared decision 
making. These approaches are based on different assumptions and have 
different practical and theoretical implications for informed consent. To help 
ameliorate some of these problems, additional conceptualizations of informed 
consent have been offered.The Nuffield Council on Bioethics (2002) 
distinction between the substantive and the procedural aspects of informed 
consent has been used in this thesis as a framework to highlight issues debated 
in the literature on informed consent.  
 
Issues related to the substantive element of informed consent include those 
relating to the underlying assumptions, principles and goals of informed 
consent. While some authors have argued that since informed consent was 
founded on the philosophical principle of autonomy of persons requiring 
researchers to respect the right of potential trial participants to self-
determination, other writers have argued that autonomous action is often 
incompatible with authority structures that traditionally legislate people‟s 
decisions. Although philosophers give different, yet supporting, 
interpretations for respecting autonomy, Meyers (1989) has objected to the 
supreme and overriding value placed on autonomy arguing that the 
independent [autonomous] self is presented as a rational will inattentive to 




In this regard issues concerning the universality and relativity of informed 
consent, particularly in terms of first person consent, in multi-cultural context 
have been widely debated. Writers have argued that cultural sensitivity in 
informed consent rests on a principle rooted in particular notions of 
personhood that are not universally valid in all cultural contexts. Many writers 
are concerned about the practical implications of westernized individualized 
notions of informed consent on participants from predominantly nonwestern 
collectivist societies. Where some writers have suggested researchers obtain 
proxy consent from trusted village leaders (Cash, 2006; Moodley, 2002), for 
example, a number of practical and substantial reasons why this may not be 
feasible have been proposed (IJsselmuiden & Faden, 1992; Bayer, 2002).    
 
Two fundamental substantive requirements of informed consent are that 
participants have the capacity to give autonomous consent and to do so 
voluntarily. Concerns about the participants from vulnerable sectors of society 
in South Africa and their capacity to consent to HIV vaccine trials have been 
raised (Ekunwe & Kessel, 1984; Ferguson, 2002; Lindegger et al., 2006). The 
question of whether children are competent enough to consent to HIV vaccine 
trials, and at what age, has been an area of considerable debate. What research 
incentives should be offered to participants and what effects inducements will 
have on the voluntariness of participants‟ consent has been raised in the 
literature as a pertinent issue that affects both the substantive element and the 
procedural elements of informed consent.  
 
The main procedural elements addressed in the literature, regarding the 
implementation of informed consent in HIV vaccines trials, centre around 
unresolved debates about how much information to provide trial participants, 
who should decide on what information to provide, what information to 
include in consent materials, issues concerning language, promoting and 
assessing participant understanding, and how to manage the interface between 




When disclosing information, suggestions have been made that to satisfy the 
legal requirement for informed consent all information required by ethical 
codes should be disclosed. However, the provision of excess or inappropriate 
information has been argued to unnecessarily complicate decision making. As 
to who should provide the information, suggestions have been made to include 
community representatives as educators. Debates concerning the type of 
information given to participants centre on the issues of scientific versus lay 
language. This links to issues around participant understanding.  What is the 
quality of participants‟ understanding particularly in terms of language 
differences and understanding complicated informed consent forms? 
Numerous studies have evaluated informed consent forms (see Grossman, 
Piantadosi & Covahey, 1994; Lindegger & Van Loon 2004; Meade & 
Howser, 1992; Tarnowsky, Allen & Mayhall, 1990) and their effects on 
participants‟ understanding. Assessing participant understanding of 
information about trials is an area of considerable debate. Although many 
suggestions have been made as to how participants understanding should be 
assessed there is an equal amount of disagreement about the validity of these 
assessment procedures (see Corbett, Oldham & Lilford, 1996; Ekunwe & 
Kessel, 1984; Lindegger et al., 2006; Lindegger & Richter 2000; Ferguson, 
2002; Flory & Emanuel, 2004).  
 
Finally, since promoting human rights protects the inherent dignity of persons 
affected by HIV/AIDS (Slack et al., 2000) it is not surprising that laws have 
made provision for the protection of subjects who enter trials. The issue of 
how the legal requirements of informed consent conflict with cultural 
demands on participants have been a topic of debate (Dhai, 2008). What 
becomes clear is the complexity of implementing an informed consent process 
that takes into account both the procedural and substantive elements in a 
multicultural, multilingual, developing country.   
 
Despite widespread acceptance of informed consent as an ethical prerequisite 
for health research, this literature review has identified many of the 
controversies around informed consent, some of them substantial and others 
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procedural.  Informed consent has been carefully implemented in HIV vaccine 
trials internationally. However, there have been concerns about the 
effectiveness of the informed consent process. This study seeks to begin an 
exploration of these issues by asking stakeholders what their concerns are 





















The literature has identified a number of contentious issues in informed 
consent in biomedical research. These issues relate to both the substantive and 
procedural aspects of informed consent. Whilst the literature has identified 
some problematic areas of informed consent that may be of relevance to HIV 
vaccine trials, this remains speculative. The aim of this study has been to 
examine the areas of concern that various stakeholders involved in HIV 
vaccine trials in South Africa have about informed consent. Are their concerns 
consistent with those issues raised in the literature, and do they raise 
additional concerns about informed consent that have not yet been raised in 
the literature? Examining what might be informing the positions stakeholders 
have on informed consent is also of interest to this study.  
 
2.1. Research design: 
 
This study was part of a broader study undertaken by the HIV/AIDS Vaccine 
Ethics Group, to examine ethical concerns about HIV vaccine trials in South 
Africa. This was an exploratory, qualitative study of data obtained from a 
sample of stakeholders in South African HIV vaccine trials.  This thesis 
focuses only on the informed consent part of this study. 
 
2.2. The sample: 
 
Key stakeholder groups were identified and selected because of their 








 Community advisory boards/groups (CABs) at HIV vaccine trials 
sites. 
 Trial site staff/Investigators, including the Principal Investigators, 
Medical Officers, and vaccine educators. 
 Media personal that had reported on HIV vaccine trials. 
 Civil society, including human rights, gender and child groups 
representatives. 
 Government representatives. 
 Research ethics committee members (RECs) who had reviewed 
HIV vaccine trial protocols. 
 Sponsors of HIV vaccine trials. 
 
Key respondents (e.g. chairs and Principal Investigators) from the selected 
sample groups were purposively sampled. Some of the respondents were 
selected using snowball sampling technique, for example, in cases where key 
respondents suggested that they knew of other more relevant persons to 
contact. The number of respondents eventually interviewed depended on the 
number in each group who agreed to be interviewed, or until the ethical issues 
identified in the interviews became redundant. Because the sample was a 
convenience sample that relied on the availability of respondents from each 
stakeholder group there was inconsistency in the number of respondents 
making up each group. The breakdown of respondents making up the final 
research sample (n = 31) was as follows: 
 
CABs  n = 5 
Site staff n = 7 
Media  n = 6 
Civil society n = 5 
Government n = 2 
RECs  n = 3 




Note: For the purposes of clarity, throughout this thesis, the terms respondent 
and representative refer to the stakeholders that were interviewed in the study 
whilst the term participant refers to the HIV vaccine trial participants that are 
referred to by the respondents. 
 
2.2.1. Sampling procedure used: 
 
Potential respondents were contacted telephonically or via email. An 
information leaflet describing the research, along with an invitation to 
participate was then sent to each potential respondent. If the respondent 
agreed, an appointment was made for the respondent to partake in a semi 
structured interview at a venue convenient to the respondent. At the scheduled 
interview the proposed research was described in detail. Respondents were 
then asked to give their consent to participate if they were still willing after 
which the interviews were recorded and extensive notes where taken. 
 
2.3. Data Collection:  
 
In qualitative research the semi-structured interview is often used as a guide 
that can be adapted to suit a particular situation (Babbie & Mouton, 2001). 
Semi-structured interviews allow for open ended questions that allow 
respondents to communicate their experiences or opinions about an issue in 
their own words, without any restrictions (Terre Blanche & Durrheim, 2002). 
In the larger study, of which this study is a part, the interviewers used a semi 
structured interview schedule. Each interview with the respondents was 
conducted in their language of choice and started with the respondent being 
asked to spontaneously list, in order of perceived importance, those ethical 
issues that they thought were a challenge in HIV vaccine trials. During the 
process of probing for more detail about the spontaneously listed issues other 




In addition, all respondents were asked to discuss three pre-identified issues; 
Informed consent, the use of children in HIV vaccine trials and the standard of 
care to be offered to participants of HIV vaccine trials. For Informed consent 
the interviewers were instructed to simply raise the issue and prompt 
discussion. All 31 interviews were transcribed and translated into English 
where necessary. This study focuses only on that part of the interview dealing 
with informed consent. 
 
2.4. Data Analysis: 
 
2.4.1. Theoretical underpinning of the qualitative data analysis used: 
 
This study was informed by a grounded theoretical approach. Popularised by 
Glaser and Strauss, Grounded theory is an analytical strategy used in 
qualitative research that stresses the “building of a theory from the ground up 
brick by brick so to speak. The bricks being the concepts that we ground as we 
proceed through the analysis process” (Babbie and Mouton, 2001, p. 642). 
According to Strauss and Corbin (1990) a grounded theory is one that is 
inductively derived from the study of the phenomenon it represents, in that 
theory is discovered, developed and provisionally verified through systematic 
data collection and analysis of data.  
 
Grounded theory holds as a basic tenet that qualitative researchers do not set 
out to test hypotheses to add to an already existing body of knowledge, but 
rather it allows the researcher to study a relatively unknown social 
phenomenon (Babbie and Mouton, 2001) such as, in the case of this study, the 
problems facing the informed consent process in HIV vaccine trials. Thus the 
data collection, analysis and theory stand in reciprocal relationship with each 
other. One does not begin with a theory then prove it but rather one begins 





2.4.2. Procedure used in developing data driven themes and codes: 
 
Strauss and Corbin (1990) identify two main processes to a grounded theory 
analysis, namely coding procedures and adjunctive procedures. Coding 
procedures include open coding, axial coding and selective coding. Open 
coding, the creation of certain categories pertaining to certain segments of the 
data text, was the method used in coding the data for this study. Thematic 
analysis was used to help the researcher organize the data into different 
categories to increase accuracy in understanding, and interpret the data 
(Boyatsis, 1998). Towards this goal, doing a thematic analysis on the data 
would allow the researcher to identify patterns in the respondent‟s responses 
which could be used to develop themes and codes. As Boyatsis (1998) argues 
a good code that captures the qualitative depth of a manifestation can be used 
to analyse, interpret and present the research. 
 
As suggested by Boyatsis (1998), themes and codes were developed from the 
data.   Whereas a theme is a pattern found in the information that at the 
minimum describes and organises possible observations or at the maximum 
interprets aspects of the phenomenon, a code is a label or definition of what 
the theme concerns. Codes and themes were generated after reading through 
each respondent‟s responses several times to enable the researcher to get a 
good sense of the material. Rather than imposing a framework on responses, 
the researcher allowed the codes to emerge as they occurred in the data 
(Weber, 1985, in Boyatsis, 1998). A sample of interviews was independently 
coded by two raters to generate a coding schedule in order to check the 
accuracy and consistency of the coding. This was done to assess for inter-rater 
reliability of the coding. Discrepancies were then discussed in detail and an 
updated schedule produced with any additional themes added. The remainder 
of the transcripts were then recoded using the pre-established list of codes and 







2.5.1. Ethics approval: 
 
Ethical approval was granted by two local research ethics committees for the 
original study.  
 
2.5.2. Ethical considerations: 
 
Before deciding about participation, the study was fully explained to potential 
participants and written material about the study was made available. Written 
informed consent was obtained from each of the participants.  
 
Of concern to the researchers were the possibilities that respondents may 
develop some negative sentiments in response to any perceived shortcomings 
of their capacity, anxiety about the possibility of social scrutiny and anxiety 
over the possibility that their responses may be divulged to the public which 
could create negative impressions of the organization the role player 
represents. Respondents may have raised expectations regarding potential 
training or capacity building as a result of the study findings. Individual 
respondents may be uncomfortable providing information on behalf of a 
certain stakeholder group and thus may require higher authority to do so. 
Respondents who may have been past or who are present HIV vaccine trial 
participants may perceive this research as being part of the HIV vaccine trial 
and that enrolment or withdrawal from one may affect their involvement in 
the other. 
 
2.5.3. Minimization of potential risks: 
 
To minimize these potential risks the following efforts were made: 1) To 
reassure respondents that the interview was not an evaluation of their personal 
or group‟s capacity, but rather that the aim was to identify the challenges of 
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HIV vaccine trials perceived by stakeholders. 2) To inform respondents of the 
proposed use of and dissemination of the data collected as well as issues of 
confidentiality. 3) To outline the potential limit of confidentiality to various 
stakeholder groups  that because there is only one regulatory authority, limited 
ethics committees, CABs and other target groups, it is possible that individual 
respondent‟s responses may be identifiable in a report of the findings, for 
example, through rich text quotes. In this regard every attempt has been made 
to summarise the data so as to make respondents as unidentifiable as possible. 
4) To interview key role players, each of whom were assured of their right to 
participate or withdraw from the study at any time and, 5) To inform the 
respondents about the potential benefits of research participation, including 
the opportunity to facilitate the development of appropriate interventions for 
















3. Research Results: 
 
3.1. Description of emerging themes and codes: 
 
On examination of the data the following main themes around Informed 
consent emerged. These included themes related to both the substantive 
requirement and the procedural elements of informed consent, which will be 
discussed respectively. 
 
Themes related to the substantive element include: 
 The capacity of participants to consent 
 Challenges around child and adolescent consent 
 Decisions about participation 
 
Themes related to the substantive element include:  
 
 Voluntariness of informed consent  
       Understanding 
 Communication 
 Information disclosure 
 The regulation of informed consent  
 The impact of context on the informed consent process 
 Challenges around informed consent  
 
 3.1.1. Participants’ capacity to consent: 
 
 A number of concerns were raised by respondents about the capacity of 
participants in the South African context to consent to HIV vaccine trials. 
Respondents were concerned about the degree of vulnerability of certain 
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sectors in society that might impact on their decision making. The issue of 
gender and power emerged. Respondents questioned the capacity of many 
women to consent to HIV vaccine research in South Africa. This respondent 
believed that: 
 “There are significant I think, gender implications 
underpinning women's participation as well, as an issue, as an 
ethical challenge.   I think the gender in its form is particularly 
mindful of the challenges that women face as a reality that 
women experience and I think it's within that context that we 
have to view women's participation in the trials.   Firstly, about 
the extent to which you can give informed consent to 
participate in the trial, and if she does, what is the substance 
and the spirit of that consent?” (Civ Soc) 
 
On the other hand, women and children‟s vulnerability to the Human 
Immunodeficiency Virus was perceived as enough reason to include them in 
HIV vaccine trials regardless of their real capacity to make autonomous 
decisions.  
 
“I do work among women and children and I've seen that a 
lot of children have become very vulnerable to HIV and Aids, 
and hence, I think they should be included in vaccine trials 
and it's clearly evident that they're not at the moment …. it's 
apparent that children are excluded from engaging into any 
scientific research because they cannot give proxy consent.   
In order to submit yourself to scientific research, you have to 
give consent on your own and in this situation, children 
cannot give consent because they're minors so hence, it 
would seem that in terms of our legislation, they will not 




In addition, some respondents were concerned that in South Africa individuals 
subjected to poor socio-economic factors are generally ignorant of their rights 
and therefore lack the capacity to make informed choices to consent to trials.  
 
“I think, because South Africa has got vulnerable groups, 
really, people don‟t really know their rights. They are really 
critical for South Africa. Particularly, Africa also because, 
because you know there are different, different eh things that 
drive people to participate. And most of them are the socio-
economic issues, really. I suspect that in America people 
know their rights, most of them, they know their rights, they 
make a choice really, not to participate, or to participate” 
(Gov). 
 
3.1.2. Challenges around child and adolescent consent:  
 
The issue of child and adolescent consent emerged from the data as one of the 
most important issues of informed consent for all the respondents. This theme 
addresses perceptions of the perceived capacity of children to give consent, as 
well as the risks and benefits around child participation. The age at which 
children should be able to consent to participation in HIV vaccine trials 
emerged as a contentious issue amongst respondents. Although the new South 
African Children‟s Act clearly sets the age at which children can consent to 
non-beneficial research as eighteen years, a number of respondents raised this 
as problematic considering the urgency of finding an HIV vaccine suitable for 
use on children. The scientific need for children to participate right from the 
start was evident in the following comment. 
 
 “I think there are four phases I think children should start 
participating in the first phase because if they do not begin in 
phase one then how are we going to determine the safety and 




Adolescent decision-making capacity was expressed as one of the main issues 
surrounding the inclusion of children and adolescents in HIV vaccine trials. 
Respondents viewed the reluctance of parents to allow children to participate 
in the trials as stemming mainly from their inability to see the need for 
children to participate, the uncertainty of whether the vaccine would work 
and their objection to their children being exposed to perceived offensive 
sexual language. 
 
“I suppose the very first thing is that you have to talk about 
sex to a child, which some people may even object to” and 
“if you're talking bringing words like penis into the 
interview,  is this going to upset people?” (Med). 
 
Respondents speculated that conflict may develop between unwilling parents 
and adolescents who want to participate in the trials. Furthermore, conflict 
related to disclosure of an adolescent‟s sexual activities was likely to interfere 
with the decision making process. A respondent speculated that:  
 
“[I]t is highly unlikely for a parent to give consent once they 
know that their daughters are sexually active. They probably, 
probably going to get an absolute fit or the daughter wont get 
parental consent because she is scared of disclosing to her 
mother that she is sexually active” (REC). 
 
One of the challenges facing the informed consent process related to 
children‟s understanding of the material disclosed. Respondents expressed the 
need for appropriate information disclosure strategies that would address the 
issues of using language more suitable to their level of understanding. 
Respondents argued that the evaluation of children‟s understanding of HIV 
vaccine research in Africa is incomparable to that of children in the West, 
however. On one hand, some respondents perceived children and adolescents 
as a vulnerable group who needed to be protected, while other respondents 
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argued that adolescents in Africa are not as vulnerable as people suspect, 
giving the impression that in general there was no real danger in the recruiting 
adolescents into the trials. Some respondents went as far as to use the different 
social demands that African children are exposed to as justification for re-
evaluating them as more competent and capable of consenting to HIV vaccine 
trials than children in the west. A respondent explained: 
 
“[T]his research is different from past research. We are re-
evaluating the risk-benefit ratio in our context. We operate in 
a different social context, where our children are not as 
sheltered as children in the west. They come from vulnerable 
backgrounds where they sometimes need to grow up fast and 
be self-sufficient” (Civ Soc). 
 
Despite this perceived invulnerability of African children, a number of 
different opinions emerged around who should consent to children and 
adolescents participation in HIV vaccine trials. One respondent was adamant 
that: 
 
“The decision/choice should be given to the community. If 
the community says   no, children should not participate” 
(CAB). 
 
Others argued that in many South African cultures it is customary for parents 
to make decisions and take responsibility for their children, which ought to 
include their children‟s participation in HIV vaccine trials:  
 
 “In our culture a child is under parents and they make 
decisions for him/her because once something goes wrong 
the parents will be responsible to correct it … As a parent 
you weigh advantages against disadvantages before giving 
your child permission no matter how old the child is”, and 
“you don‟t want to get any old Tom, Dick and Harry to sign 
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your child, you want to get a legal, a legal guardian, and if 
there is none, then you don‟t involve the children” (CAB). 
 
Not all respondents agreed with parental consent, however, advocating the 
child as the decision-maker. Some argued that consenting to participate in 
HIV vaccine trials is no different to consenting to having an HIV test. There 
were also some unexpected issues raised. For example, parents could exploit 
their children for their own personal gains, for example.  
 
“[B]ecause children can‟t give consent themselves …so that 
means they‟re dependent on their parents…and I don‟t know 
how you can ensure that the parents are not using this to for 
their own personal gains or needs versus that of the child…” 
(Civ Soc).  
 
“But then going back to the fact that these are, well helpless 
children, we, the mothers, could be drunkards, could be so 
desperate…I mean they could want this children to be 
involved in research just because they are looking at getting 
paid and not caring about the consequences to the child‟s life 
at all…” (CAB). 
 
“…It may be easier for a parent to accept an incentives if 
they‟re not putting themselves in the risk but rather their child” 
(CAB). 
 
3.1.3. Decisions about participation:  
 
How decisions to participate in HIV vaccine trials should be made, and who 
should make them emerged as a theme. Even though the substantive 
requirement of informed consent requires individual autonomous decision 
making some respondents argued that two levels of decision making that 
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includes both the community and individuals was more appropriate in the 
South African context, where collective decision making may be viewed as 
part of most collective cultural practices. Using the community as gate 
keepers for access to individuals was seen as essential. Respondents suggested 
using community representatives to scrutinise proposed research in the area to 
protect individuals and facilitate the decision making process: 
 
“[T]his will enable us, the community members, to discuss 
the research and see if it is harmful or not to the community 
based on our different cultural practices and beliefs. To 
review the questionnaire, and see if it raises hopes to the 
potential participants or not. The community should be 
informed from the start about the proposed research” (CAB). 
 
A contradictory suggestion was also made, however, questioning whether 
community members were really as powerless or vulnerable as claimed. 
Respondents advocated    making use of an existing participant base of more 
empowered individuals, perceived to be better able to make and take 
responsibility for their own decisions regarding the research. Interestingly 
literacy was perceived as the main criteria of empowerment and thus the 
ability to protect one‟s rights.  
 
 “[I]f you have got a participant base that is a little bit more 
literate, more empowered, those are the type of participants 
that can protect their own rights” (Sponsor). 
 
Concerns were raised about the potential consequences of not getting 
community consent since without it some participants would be unduly 
ostracized. For example a respondent warned: 
 
 “If in the opinion of the community says „no children should 
not participate‟ then they should not,  meaning; the children 
would go back to the community and find it difficult to 
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mingle with it if they participated without the community‟s 
approval, but if it says, yes, it  does not matter what the law 
says” (CAB). 
 
 3.1.4. The voluntariness of informed consent: 
 
With voluntariness being a major component of the substantive requirement of 
informed consent, respondents were concerned about offering incentives to 
participate in HIV vaccine trials.  The influence of incentives could undermine 
the voluntariness of participation. If incentives were too great they could act 
as undue inducements particularly in the context of poverty. Respondents 
argued that incentives can also hamper understanding: 
 
“[L]ike I mentioned about the school children doing it for 
money, you know, that perhaps, you know, sometimes people 
don‟t even look at the issues, you know, they might be 
interested in what they are going to get out of the trial in 
terms of money” (REC).  
 
Some respondents were ambivalent about how and whether offering 
incentives would effect participants‟ decisions to participate, however: 
 
“I mean the issue of remuneration, and incentives for 
participating in research. You know, sometimes, the money 
itself distorts the whole purpose of the research. At the same 
time, the money itself encourages, you know, people to. So I, 









3.1.5. Understanding of the material disclosed:  
 
The issue of understanding of trial related information was identified as an 
issue in informed consent. Given the complexity of HIV and vaccine trials, 
some respondents thought that understanding needed to begin at the level of 
the broader community as a prerequisite to the individual informed consent. 
This should begin with broad HIV/AIDS education.  Better community level 
understanding of HIV/AIDS and vaccine trials would facilitate community 
buy-in, and it was important to understand and respect the community 
perspectives from which research participants were selected. One particular 
reason advanced for beginning with broad HIV/AIDS education would be to 
dispel false beliefs and myths some participants may have about HIV/AIDS, 
which may affect understanding of HIV vaccine trials, such as believing that 
if they get a vaccine then they will be safe from HIV vaccine Trials, 
potentially increasing their levels of risk taking behaviour, as well as the false 
belief that it is HIV infected people who participate in trials. This was 
illustrated beautifully by saying;   
 
“It [understanding] is especially critical when you are dealing 
with HIV because it is a field where there is a lot of gobbly 
goop and misinformation and pseudo science ok? And there 
is, it is very easy to presume that an HIV vaccine is an act of 
in fact infecting people with HIV” (CAB).  
 
However, broad HIV/AIDS education could be potentially complicated by the 
growing AIDS fatigue around HIV/AIDS information in SA.  There was 
some concern that this may affect the desire to participate in the research.  
 
The need for participants to understand the personal implications of 
participating in HIV vaccine trials and not just the general risks and benefits 
was viewed as an essential component of informed consent. For example, 
participants would need to be aware of the risk of stigmatization when seen at 
the HIV vaccine trial sites by members of the community, particularly in the 
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South African rural communities who are presumed to be less educated. 
Respondents felt that participants of HIV vaccine trials would need an 
understanding of the risk of stigmatization against trial participants from the 
community, insurers and others.  
 
“[F]or instance, if you had to test, if you were a young 
person, okay, but if you want to take life insurance and you 
have your HIV test done okay you will have your certificate 
from the trial that you have participated in this trial but still 
the insurance company is going to say but you could have got 
HIV since then” (REC). 
 
A number of challenges were raised concerning participant understanding of 
the information.  Challenges to understanding included various cognitive and 
educational issues such as illiteracy, limited formal education, difficulty in 
understanding scientific concepts and the lack of scientific concepts in 
indigenous languages. It was even suggested that educators themselves often 
do not always understand the information.  
  
There was inconsistency in whether the exclusion criteria for informed 
consent are discriminatory toward certain participants and therefore unethical. 
For example, the requirement that participants have a certain level of literacy 
would unnecessarily exclude participants who have the capacity to understand 
trial related information in another medium. 
 
 “Again you‟ve illiteracy issue going on here and so there is 
discrimination there too because they are demanding literacy, 
they are demanding English speaking and everything and so 
therefore they kind of excluding a lot of people who has a 
potential to understand and to benefit” (REC).  
 
This argument was not shared by other respondents, however, who argued that 
the exclusion criteria for informed consent was appropriate for the illiterate as it 
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would serve to protect them from coercive practices by researchers. A 
respondent explained:  
 
“[M]y attention was drawn to it by the participants who come 
in and say now what if I couldn‟t I couldn‟t speak and I 
couldn‟t read or write, my parents haven‟t sent me to any 
school and empower me and the way you saying I could read 
a paper and sign it you know and what would you do? Would 
you just take me because I‟m 20 years old? I‟m young and 
I‟m HIV negative you know” (Site Staff).  
 
Illiteracy was seen to complicate participant understanding, even though some 
argued that illiteracy does not imply stupidity. Participants with lower 
education levels were seen as being more vulnerable to exploitation affecting 
the voluntariness of the consent given. Being well educated was seen to 
guarantee understanding because of the difficulty of many of the concepts.  As 
a research ethics committee representative pointed out: 
 
“Eh, I can‟t understand them and I have a PhD and I am an () 
Scientist and I can‟t understand them … And I can show you 
the evidence but I do not think that they, it is realistic for 
them to understand all these concepts, okay” (Gov). 
 
Assessing whether participants really understand the information required for 
them to give informed consent was seen as a likely challenge, with a special 
concern about how understanding would be assessed. A Research ethics 
committee representative elaborated on the inadequacy of assessment 
practices in one of the HIV vaccine trials:  
 
“[T]he counsellor made some brief attempt to try and check 
comprehension using yes/no question. We came in 
afterwards and did the narrative thing and where she had 
signed on and said yes I understand everything and I mustn‟t 
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get pregnant and all those things. When we asked her she 
said eh I am signing on to this trial because my boyfriend 
sleeps around and ehm because I am HIV positive now eh 
and I need to enter” (REC).    
  
Respondents suggested that assessing understanding would need to be an on 
going process, which required different methods for different communities. A 
suggestion put forward was that assessing understanding could take place 
through feedback, where participants are asked to repeat the information given 
to them back to the educator.  
 
Various participants expressed concern about the consequences of lack of 
understanding of HIV vaccine trials by participants and community members, 
such as increased fear and distrust resulting in increased attrition from the 
trials, participants having false expectations or unrealistic hopes, and not 
realizing that they have the freedom to withdraw from trials at any stage. A 
respondent argued that: 
 
“[W]hat is important for me is that they understand that they 
are under no obligation to complete the contract with us, you 
know they can terminate the contract at any time and um they 
will not be shamed or shouted at or prejudiced or anything 
like that” (Site Staff). 
 
With informed consent being a legal requirement, some respondents were 
concerned that a lack of understanding by participants may lead to legal 
retaliation against the trial site by participants claiming that they were not told 
about certain aspects of the research. Respondents offered various suggestions 
as to how best to facilitate understanding. These suggestions varied from 
using key people in the work place as educators, being aware of possible 
power differentials that may exist between the research educators and 
potential participants and regularly reminding participants about various 
aspects of trials. Some mentioned that responsibility for facilitating and 
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assessing understanding rests mainly on the principal investigators. Although 
the research investigators were not expected to actually assess participant 
understanding themselves they were expected to ensure that there are enough 




Given that understanding is a crucial element of informed consent respondents 
emphasized the importance of communication in facilitating understanding. 
Good communication was seen as the key to informing participants about 
different aspects of the trials. Stakeholders‟ understanding how best to 
communicate with people was seen as an essential moral requirement of 
informed consent, as was expressed in the following.  
 
“I think the moral imperative is first to understand as best we 
can, how to communicate with people and make a very, very 
careful and sincere effort to communicate with them, and to 
exclude them if it is clear to us that they can‟t get it” 
(Sponsor).  
 
Respondents described communication and transparency as making up the 
two main pillars of informed consent with communication being seen as 
having the power to allay fears about the risks of participating in the trials, for 
example. 
 
“I think there was very little fear on the part of the 
volunteers because they had had very clear communication 
and they were kind of ready for hearing something you know 
a little bit, they understood that it was a little bit risky, but 




Concerns were raised about white researchers in general not being sensitive to 
the needs of black community‟s understanding of research, resulting in 
participants not being given the chance to communicate their non 
understanding of information given.  
  
“As I said, these things (research) are very difficult and sometimes 
people who are conducting the research are white people and they 
think we understand research as they do. And most often they miss 
the point that we should be given that opportunity to say I do not 
understand” (CAB).  
 
In order for participants to „buy into‟ and trust what they were being told 
about the trials it was suggested that clear and transparent communication 
would need to happen between the researchers and community leaders. 
Communication at this level could facilitate understanding and ameliorate 
potential problems between principal investigators and trial participants.  
 
“[T]he relationship between the principal investigator and the 
participants is problematic. It‟s usually mediated by a host of 
other individuals whose training is not necessarily uniform, 
whose background is not necessarily uniform, whose notions 
are not necessarily uniform and whose language, though 
maybe the language of the participants in the study, may not 
necessarily be. So I think there are layers of communication 
breakdown, which are horrific” (REC) 
 
To facilitate understanding respondents expressed the need for communication 
to be a two way process between the principal investigators, other 
stakeholders involved, and the trial participants. In addition, respondents felt 
that reciprocal communication between different trial sites in the country 
would help stake holders identify and find solutions to problems experienced 




3.1.7. Information disclosure: 
 
Respondents were concerned about how, what, and how much information 
should be disclosed to participants. Information disclosure to, and education 
of participants emerged as one of the main themes concerning informed 
consent. This theme incorporated concerns about how information should be 
given to research participants as well as the potential dangers and challenges 
that may be involved when doing so. 
 
Respondents felt that with transparent and clear information, participants 
would be able to make informed rather than coerced decisions to participate.  
 
“I think also that with transparency people can then make 
better decisions…you know, If I know all the possible or 
known facts then I can make a better informed decision.” 
(Site staff) 
 
Stakeholders agreed that information would need to be disclosed at all levels 
to ensure uniformity of information given to participants across different 
stakeholder groups, as was expressed in the following: 
 
“Ja … So you actually tackle it at all these levels (I: Ok) at 
the same time and obviously you need to make sure that they 
all get the same information so that at the end of the day they 
they‟ll hear the same thing from three different groups of 
people, not everyone had their own story about it” (Site 
Staff). 
 
Although the substantive requirement of informed consent hinges on 
individual autonomy respondents raised the issue of broad community 
education about HIV vaccine trials as a prelude to individual education. In this 
regard using key players in the community to disseminate trial related 
information to participants was suggested, due to the availability of a number 
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of groups in communities that could be used to facilitate this process. The 
media particularly was perceived as having an important role in disseminating 
trial related information to communities. Some respondents questioned how 
accurately information was being portrayed in the media, however. It was 
apparent that tension existed between media houses wanting to sensationalize 
media stories about the trials and journalists wanting to report the facts about 
the trials. Dealing with the tension between giving accurate information and 
producing interesting stories that would sell newspapers was difficult for 
journalists. This was expressed by a media representative who said: 
 
  “I feel torn between, I feel the dilemma between being part 
of what I feel is an advocacy struggle … One of my strengths 
and real interests is building a bridge between what I can 
establish with credibility is the correct, ethical and scientific 
way forward with emphasis on the scientific, that‟s my stuff, 
and then using my skills to educate but at the same time I 
also have to try and tell the story” (Med).  
 
The question of what and how much information to disclose to participants to 
constitute legitimate informed consent emerged as a dilemma. One begins to 
see in the data quite clear inconsistencies around what and how much 
information respondents thought should be disclosed. On the one hand, there 
was the perception that researchers cannot be trusted, thus motivating the need 
to give participants all trial relevant information, for example: 
 
“[A]ll the knowledge, all the information that‟s available (I: 
Ja) and as information becomes available that should be 
transmitted or communicated with your participants or 
whoever you are involved in so that they know what is 
happening” (CAB). 
 
And yet, there was concern about the overloading of information. 
Respondents argued that discussing hypothetical risks to participants which 
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may not be relevant provides excess information that distracts the participant 
from the vital information needed for informed consent: 
 
“[T]he kind of example of putting a hypothetical risk that is 
very um developed country centric and trying to explain it to 
somebody, and I think you just distract their attention and  … 
they‟ll spend so much time trying to figure that example out 
that they won‟t be able to focus on the things that have 
relevance to them” (Sponsor). 
 
On the other hand, other respondents argued that one should disclose 
information only relevant to participants‟ specific needs, for example: 
 
 “So it has to be specific to that person, the education can‟t 
just be generic. You can‟t just say well you know, there‟s 
…there‟s all education for all the people …it has to be 
specific to, you know the type of person that‟s coming 
forward” (Site Staff). 
 
A possible explanation for this inconsistency became apparent in the various 
types and levels of suspicion that emerged, whereby respondents would 
question the validity of the informed consent process. Some respondents 
warned that with knowledge comes power as was demonstrated historically in 
the South African context of Apartheid where knowledge was withheld from 
the public leaving the public vulnerable to coercion.    
 
“I think that we need to realize that information is power, or 
knowledge is power and with that knowledge you can begin 
to influence people … there was knowledge that wasn‟t uh 
used to inform people properly so that‟s why communication 
is so important and I mean we come from a history where uh 




Some respondents claimed that information about certain aspects of the trials 
was being withheld from participants to the extent that participants themselves 
became suspicious enough to want to withdraw from the trial. There was fear 
that communities were being exploited by the researchers who did not explain 
the facts about the research to community members in a way that would allow 
them to make adequately informed decisions about research taking place in 
their community. The suspicion was that researchers almost bullied their way 
into the communities who were then told what would happen, for example: 
 
“ [W]hat sometimes happen is that, let us say, there is a study 
that is to happen in the community, so just like they come 
and tell us, but or explain, but not explain that in a way that a 
person would understand, but just to tell us that this is what is 
going to happen” (CAB). 
 
An additional concern was raised where the FDA legal requirements of giving 
participants all the trial relevant information conflicted with various 
stakeholders‟ experiences that a large proportion of the South African 
population do not understand all the legal jargon. An exasperated respondent 
asked: 
 
 “I mean have you seen those consents? I mean you fall 
asleep on page three!” (Site Staff). 
 
These concerns reflect the procedural difficulties experienced when importing 
ethical concepts such as informed consent from developed countries and 
trying to apply them to different contexts. Respondents suggested that to 
ameliorate this problem procedural adjustments would need to be made during 
information disclosure to facilitate understanding. 
 
“What we need to probably have is a very brief patient 
information leaflet and modified informed consent that is 
applicable to the south, the region that unpacks the main 
68 
 
informed consent. And then once people understand that one, 
you then go … through the, the really complicated informed 
consent, so that you basically start with something simple, 
that a bit more complicated and then go through the kind of 
FDA required informed consent” (Site Staff).  
 
Using the right strategy to educate or disclose information to participants was 
seen as important. Some respondents argued that it was not necessarily the 
layout of information on the informed consent forms that need to be 
challenged but rather the way in which the information is articulated and 
disclosed to participants. Some participants argued that a multi-level 
education strategy needed to be set up. For example: 
 
“I think um I guess the easy answer is that you have to have a 
good education strategy that is um culturally appropriate and 
preferably in …the potential participant‟s home language um 
and that‟s an ongoing thing, so its not all the information in 
one session but that there are repeated opportunities to get 
concepts across and for people to ask questions and then 
again once they enrol its an ongoing process that they, that 
you keep giving them information, reinforcing concepts” 
(Site Staff). 
 
While another respondent suggested simplifying difficult scientific jargon into 
terms that participants would understand: 
 
“[W]e have got to make it so easy and speak about soldiers 
that protect people from infection. Because when you even 
before you mention phagocytes and microphate macrophage 
you see, it is far fetched from people, so people must first 
understand when you speak about those that they patrol the 
phygosite/hagocyte and those that will withhold the infection 
the microphatemacrophage, you see? You have got to 
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elucidate the scientific jargon, because if you just go jargon 
and you will be speaking microphageshatism that is very 
difficult to understand” (Gov).   
 
Not all respondents thought that the informed consent forms should go 
unchallenged, however. Some respondents argued that the informed consent 
forms were too lengthy, too legalistic and included irrelevant information. In 
addition, the layout of the forms as well as the language used was not easily 
understood by participants. Respondents indicated that attempts to address 
these problems were being investigated, however.   
 
“Part of our research has been modifying the form using 
pictogram changing the order of the form, putting important 
things up, first checking comprehension and those kind of 
things”  (REC). 
 
Other challenges pertaining to the disclosure of information also emerged. 
Concerns were raised regarding whether participants who speak a different 
language to the language being used by the educators disseminating the 
information, would have sufficient understanding to be truly informed about 
the trials. The need to communicate in English as well as the local language of 
the community from which participants would be drawn was viewed as 
essential.  
 
“One of our standard operating procedures is that informed 
consent has to be in a local language. I mean patient 
information leaflets, videos anything that you get or if you 
are putting up posters in that community is all got to be in a 
local language” (Site Staff). 
 
Related to the issue of language concerns were raised about the use of 
translators in disseminating information. Respondents argued that translators 
would need to consider the vernacular of the language spoken by different 
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cultural groups. The difficulty of translating scientific jargon into a language 
where such concepts do not exist was also raised. Some respondents suggested 
simplifying complicated scientific jargon before translating the information 
into other languages as a possible solution.  
 
3.1.8. The regulation of informed consent:  
 
Respondents raised questions regarding what laws or regulations should be in 
place to regulate informed consent.  Again, conflict was evident between 
those respondents who believed informed consent should be regulated and 
those who thought it shouldn‟t. Some respondents were suspicious that trial 
sponsors from wealthier, developed countries, who were under pressure to 
recruit large numbers of participants, would be tempted to cut procedural 
corners when obtaining informed consent from participants in developing 
countries they perceived to be less educated. These respondents argued that 
informed consent needs to be strictly monitored with tight regulation that may 
necessitate legislation. One respondent went as far as to suggest that the media 
could play an important policing role in giving participants a forum in which 
to complain if they felt their consent was not legitimate.   
 
“[P]olicing monitoring role, you know if the vaccine trials 
are not working or if someone feels exploited, they should 
feel that they could come to the media and say that this is 
how I felt, this is why my education ….I didn‟t think that 
they, ….I didn‟t consent properly” (Med). 
 
Not all respondents agreed that informed consent should be so tightly 
regulated. Some respondents were worried that excessive regulation would 
stop trials from taking place. Over regulation was predicted to create potential 
conflict between those stakeholders who were under pressure from the 
community to comply with certain cultural practices and following prescribed 




3.1.9. The impact of context on the Informed consent process:  
 
Respondents raised the issue of the impact of context on informed consent. 
Factors such as poverty, power relationships and other vulnerabilities were 
seen to affect the capacity of participants to make informed decisions. Some 
argued that there are many communities in South Africa who may be easily 
manipulated into participating in trials because of their perceived 
vulnerability.  
 
“[Y]ou can go into many of our population, of our black 
population, with a lesser education … but sometimes you 
know, it‟s easier to persuade people with a lower education 
level, um, ok when you are coming into a trial” (Site Staff). 
 
It was argued that there is an historical context of African people respecting 
“white authority” in South Africa. The implication was that African 
participants who still continue to view the HIV vaccine researchers as in a 
position of authority may not feel they can refuse to participate in trials.   
 
“It is important that in most cases, most people will have an 
investigator who happens to be white and they happen to be 
Africans, and coming from this disenfranchised type of 
history where we come from, most participants are still under 
that belief that the investigator knows it all, and theirs is just 
to sign the informed consent” (Sponsor).  
 
Some sectors of South Africa‟s population were viewed as never having been 
allowed to make their own research decisions. An interesting contradiction 
emerged when, in one breath, a respondent complained about how hierarchical 
decision making, historically the norm in the mining industry, violates the 




“[T]hey still experience research as something being decided 
by the mining um, or mine management and they kind of 
forced to take part whether they want or not” (Site Staff). 
 
And, in the next breath, he or she indicated how the miners had become so 
accustomed to having the mine management handle their affairs that they 
actually preferred to have decisions made for them.   
 
 “[I]n the past they probably relied on these people to handle 
all their matters whether it was finances, working conditions 
or, um … and that‟s just a culture that came from all of that, 
now they are depending on, or still in this system of 
everybody else having to make decisions for them” (Site 
Staff). 
 
In addition, miners were also seen to be influenced by their co-workers, 
hinting at a preferred collective decision making process. 
 
 “So and unfortunately you know a lot to these men, don‟t 
feel they are in a position where they can actually voice their 
own opinions and make their own decisions of … it‟s not 
only by the mining um structure but also their, their co-
workers” (Site Staff). 
 
3.1.10. Challenges around Informed consent:  
 
The need to get informed consent for a variety of procedures was seen as an 
administrative challenge since different separate informed consent procedures 
would need to be done at various times during the trial. One person speculated 
that: 
  
“maybe five years down the line where we are putting 
needles into them and we have to get consent for that, which 
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is gonna be separate and we might have to get consent for 
blood testing and counselling but not necessarily for 
questioning interviews” (REC).  
 
Some respondents argued that the substantive requirement of individual 
consent may be challenged by cultural expectations. In cases where there may 
be cultural differences in decision-making that demands collective or shared 
decision making, for example, the procedural elements of informed consent 
may need to be adjusted for the South African context.   
 
“Although the Constitution gives all rights, there is a need to 
consider this issue because of cultural practices. It may be 
advisable to involve both partners in seeking prior consent. I 
don‟t know how this would work but it would depend on the 
cultural group. If both partners agree, it may be easier” (Civ 
Soc). 
 
Trying to “sell” the trial to participants versus obtaining genuine Informed 
consent from them was a concern expressed by some respondents. The tension 
between encouraging participants to join a trial, in order to recruit large 
numbers of participants needed for stage three trials, and ensuring that they 
are adequately prepared to make an informed choice was raised by a 
respondent who suggested: 
 
“We really have got to weigh the pressure of recruitment of a 
large number of people against truly enrolling truly informed 








3.2.    Findings by stakeholder group: 
 
3.2.1. Civil society: 
 
The Civil Society group tend to see themselves as caretakers of society. It was 
important to civil society representatives that both participants and 
communities have a good understanding of trials and the personal and 
community implications of them. Thus it was not surprising that they felt that 
participants and, especially, communities should be fully engaged in decisions 
around participation.  As one respondent stated: 
 
“Civil Society must engage the process, absolutely. You 
know, what and that's round what is the product?   What does it 
mean for people participating in the trial?  What does it mean 
for community?   You know what I mean?   Who are making 
the decisions around the trials and to what extent can 
community be involved in the decision making processes? So 
literally at every level and in every aspect, community should 
be central” (Civ Soc). 
 
Context related issues perceived as affecting participants‟ autonomy, such as, 
poverty, lack of education, lack of social power and specific vulnerable groups 
such as rural women and children were main concerns for Civil Society 
representatives. For example a Civil Society representative asks: 
 
“How do you do a trial that involves poor people, or people 
who are not very well educated? While another Civil Society 
representative suggested “There are definitely South African 
specific issues in terms of our social situation and 
epidemiological issues. While there are generic ethical norms 




Information disclosure to the public about HIV vaccine trials was also an 
important issue for civil society representatives, for example: 
  
“The results of these things are important. It should be more 
publicly disseminated. Information should be accessible to 
all. It should be made more public” (Med). 
 
3.2.2. Community Advisory Boards: 
 
For the Community Advisory Board Representatives the issue of 
communication was of prime concern. A Community Advisory Board 
Representative proposed that communication needed to be: 
 
“properly set up, I prefer starting with the CAB itself then 
moving to a trial site to the site, and then also to have 
communicated with, with what is happening at other CABs 
(I: Ok) within our country and then to extend that into 
Africa”  (CAB). 
 
Most Community Advisory Board Representatives expressed the importance 
of setting  up community advisory groups to facilitate community 
involvement from before the trials start as a means of empowering the 
community in preparation for HIV vaccine trials and thus by implication 
aiding the Informed consent process. A Community Advisory Board 
Representative said:  
 
“The people who are involved in the vaccine have made a 
very good step to say that we should form a CAG before a 
trial itself starts. It empowers the community to know exactly 
what is happening around us…I can say that community 
members need to be involved and should be given a chance 
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to voice their concerns even before everything else starts 
(CAB). 
 
The importance of educating the Community Advisory Board Representatives 
first was seen as crucial since the role of Community Advisory Board 
Representatives is seen as primarily to: 
 
“[L]ink researchers and the community. Meaning if there is a 
planned research these people should be the ones to 
disseminate information to the community and hear their 
concerns and refer them back to the researchers. These are 
the spokespeople on behalf of the community… As a matter 
of fact even before we go and educate the community down 
out there, the very people who are going to be educating the 
community need to be educated too” (CAB). 
 
Even though the perceived function of Community Advisory Board members 
is as spokespeople on behalf of the community, a Community Advisory Board 
Representative ironically worries that miners may feel pressured by the 
researchers into recruiting for HIV vaccine trials, stating: 
 “We were worried that maybe miners were chosen just 
because they are miners and they would easily agree to 
participate in the research just because researchers said they 
should” (CAB). 
 
3.2.3. Site staff: 
 
How context impacts on the informed consent process was an important issue 
for site staff representatives. When speaking about the plight of mine workers 




“The whole history of um the mines it‟s one of, you know 
they work at the mine and they, they kind of they‟re 
controlled by the mining bodies... a lot of decisions were 
made for them in the past by either their um labour 
representatives or the mining representatives and that now 
actually poses problems for us because um, they still 
experience research as something being decided by the 
mining um, or mine management and they kind of forced to 
take part whether they want or not”. What happens when you 
do informed consent on an individual level?  Do people say 
no, even if the whole group of them think that they want to 
take part? (Site Staff) 
 
The issue of undue inducements that offers incentives to participate in trials 
was also seen as problematic, as it may affect the voluntariness of 
participants‟ consent. Of particular concern was the offering of financial 
rewards to participants from socio-economically vulnerable populations, as a 
site staff representative said: 
 
“[F]inancially if there any anything that is a financial gain to 
them they‟ll probably participate just to do, just to get the 
money and not because they want to … or understand the 
study.  Um, I think that makes both communities vulnerable.  
In the general community you get a very high level of 
unemployment” (Site Staff).  
 
A second site staff representative highlights this issue when suggesting that 
when offering incentives researchers:  
 
“[N]eed to be very careful um, you know, how you structure 
it because um, well for our mining community for example 
they if if you want to give them money for transport costs or 
something like that that is going to be an incentive to them to 
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do it, to get the cash because they have free transport (I: Oh, 
ok) provided by the mines (I: Ok) where in the general 
community you don‟t have that.  Um, and if you want to give 
them something, you know, something like food or 
something you know for the mining community would be 
better to use – a better incentive to use than you know, giving 
them money for transport costs where the general community 
would definitely use that money for transport because that is 
the only way they can get to, to the research site and back 
home” (Site Staff). 
 
An example of how undue inducements can affect the voluntariness of 
participants consent was realised when participants continued to come back 
for the monetary rewards offered in other clinical trials they had participated 
in: 
 
“[W]hen we did a lot of clinical trials for them.  And they 
pay participants an amount per visit every time they pitch up 
and, you‟ll find people coming for you know their visits and 
then after the study is finished you know they would come 
back still on a monthly or two weekly basis and say “Now 
ok, where‟s my money?”  (I: Oh dear) So we realised well 
ok, that is a bit of a problem because they are only coming to 
get the money and nothing else” (Site Staff). 
 
The issue of who makes decisions to participate in the trials, the community 
versus individuals, was also of concern to site staff representatives. A site staff 
representative emphatically stated that: 
 
“You don‟t speak to the Induna to give consent for the whole 





3.2.4. The Media: 
 
Understanding the personal impact of consenting to trials was one of three 
main concerns voiced by the media representatives. A media representative 
was concerned about participants‟ ignorance of how media articles can 
potentially stigmatize them if their identity was inadvertently mentioned. The 
suggestion was that during information disclosure this possibility should be 
discussed with participants in order for them to make informed decisions. 
 
“I‟m very aware of it because I work in HIV, and do lots of 
HIV stories, and I know that anytime someone is identified 
with anything to do with HIV or AIDS, it can have 
repercussions: it can be negative, they can be positive, but 
people must be very aware of what they, um, are getting into.  
And I think journalists are very casual about it: where they‟ll 
use peoples‟ names and identities without thinking about it” 
(Med).   
 
The important role that the media plays in educating the public about HIV 
vaccine trials was acknowledged. Education of the public through the media 
was seen as an important information disclosure tool in the informed consent 
process to prepare participants. Media representatives raised the issue of 
AIDS fatigue within the media and the general population. Aids fatigue was 
seen to be problematic in that it may affect coverage on HIV vaccine trials by 
the media and the motivation of individuals to read information about the 
trials. For example, a media representative pointed this out in the following:  
 
“[B]ut the downside of it is that there is a high increasing 
amount of AIDS fatigue, which I have, I pick up a lot even at 
the level of my newsroom you know, um they have just had 
enough, you know. It‟s like how many more times can you 
write about like AIDS …Then there‟s a high level of AIDS 
fatigue amongst our readers. You know, we‟ve had a survey 
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were we found that anything on AIDS on the front page, 
when I write a story on the front page, our circulation drops” 
(Med). 
 
The issue of lay versus scientific knowledge about HIV vaccine trials was a 
concern of some media representatives who questioned whether „true‟ 
informed consent could ever be achievable if participants did not understand 
the information given to them. For example a media representative proposed: 
 
“I think that it is incredibly important with all research to 
ensure that you have true informed consent. Um, however I 
think often what happens isn‟t true informed consent. And I 
think that to a degree, true informed consent is never really 
possible. Because the person who is required to be the subject 
doesn‟t have the same scientific knowledge that the scientist 
has…” (Med). 
 
The authenticity of the in informed consent process in terms of whether 
recruiting participants for HIV vaccine trials is a voluntary or coercive process 
was also questioned by media representatives as was expressed in the 
following quote: 
  
”Um, I think the most important one would be about 
participation, about the whole process of getting volunteers. I 
would imagine, is a, is a (dice) between needing to be 
somewhat persuasive because you want volunteers, and at the 
same time needing to be actually sure that it is informed 
consent. And you need to ensure that um, ja that no-one has 
been forced into it and that they understand the dangers and 
the implications of participating in research” (Med). 
 
However, offering incentives to participants in HIV vaccine trials was not 




“Ja, it‟s an incentive, I don‟t think it‟s a coercive thing. It 
should be an incentive for people to sign up, but hopefully if 
they‟re signing up for a vaccine trial, they‟re very well 
informed and they‟re not going to put themselves at high risk, 
anyway: even though I know that‟s not true (laughs).  I think 




The disclosure of information to and the education of participants, as well as 
their understanding of the information given, were identified as important 
issues that impact on informed consent by government representatives. This 
was demonstrated by the following statements made by a government 
representative: 
 
“This issue is so critical you gonna have to make sure that 
you reach people from where they are, and there are so many 
people who are illiterate in the country (    ) English does not 
mean a thing to them, and those are the people who in fact are 
mostly at risk for HIV infection and if we do not reach them 
then we will miss the bigger population … You have to use 
the language that people will understand and the way the 
messages, should be context specific, culturally sensitive so 
that they can contextualise, they can understand the construct, 
how they construct the messages to be meaning what they 
intended to mean” (Gov). 
 
Government representatives were also concerned about the issue of children 
and their capacity to consent to participation in HIV vaccine trials. Children 
were also seen as vulnerable to exploitation and thus the need to monitor the 
Informed consent process was seen as vital, as is seen in the following quote 




“The issue of consent, I have already raised it. So I think that 
one should be monitored really very well. To say who, who, 
who consents, for the child, because you see if there are 
incentives, and then there is an agreement that children are 
going to participate, and then the child is not staying with the 
biological parents, for example, and stays with 
a…..grandmother or so, if that grandmother is coerced or is 
of the opinion that, you know, she needs the money, she 
might, she might consent for the child to be part of the of the. 
So we need to balance that issue to say, who should really 
consent for the child?” (Gov) 
 
Having suggested that the consent process should be carefully monitored, 
however, the same government representative also suggested that the 
Informed consent process does not necessarily need to be strictly regulated 
when he or she suggested: 
 
“You know in terms, I think in terms of ethics, you can 
regulate up to a certain extent, really. You can‟t just regulate 
totally. I think we will use the guidelines as a reference 
really. I don‟t think there is anything that you can change, 
unless, from the outcomes, of the trials, something drastic is 
really endangering the people, we will need to look at the 
guidelines, but I think for now, the guidelines really form a 





The sponsor representatives raised the issue of the complexity of informed 





“Well we had an interesting discussion about this in which, 
internally, we were talking about the complexity of consent 
forms, and one of my colleagues asked me, well who is it that 
makes you make these so complicated? We were agreeing 
that they are too complex” (Sponsor).  
 
All the sponsor representatives raised the issue of communication between 
different stakeholders involved in HIV vaccine trials and the community. The 
difficulty in reaching consensus between them about how to proceed with the 
ethical requirements of the trials was expressed by a sponsor representative, 
for example: 
 
“You know there is a lot of players, WHO, all the way down 
from WHO to the people at the community level to the press, 
uh, who come in with different levels of beliefs and 
information, so trying to get all those people to agree on how 
to proceed is difficult … I think that it‟s a good thing to have 
open discussion with a lot of different players, sometimes 
you just have to be patient with people who have their own 
concerns and let them work through it themselves. But I do 
think that discussing as opposed to just filing written 
documents or whatever is sometimes very helpful” (Sponsor). 
 
3.2.7. Research Ethics Committee  
 
Most of the Research Ethics Committee representatives expressed an 
awareness of their responsibility towards the safety of participants in research. 





“You know, we are going to be using vulnerable people and 
you know how are we going to make sure that these 
vulnerable people are not exploited” (REC). 
 
 Participants‟ lack of knowledge to adequately protect themselves, and thus 
give fully autonomous consent, was identified as problematic for the informed 
consent process. For example, a Research Ethics Committee representative 
stated: 
 
“Because of a responsibility that eh one holds in ethic issues, 
that science evades ethics. One the most important things is 
the safety of the patients particularly in population where 
they don‟t have knowledge ability to protect themselves” 
(REC). 
 
How well informed they could be in regards to the unknown risks and the 
safety of participants of an HIV vaccine was also identified as an issue, as was 
expressed by a Research Ethics Committee representative in the following: 
 
“[Y]ou see of all these things interconnects because the 
informed consent relates to our adolescents and our children, 
illiteracy and the understanding of the whole concept of the 
HIV/AIDS virus, you know the particular population being 
studied have so much myths and difficulties with the 
concepts and coming into vaccine trials you must be coming 
into something that is gonna kill you. So informed consent 
means that they know really what they are coming into and 
that they have a right to decide. And it concerns me because 
we don‟t really know what the risks are to explain to people” 
(REC). 
  
Despite concern about the unknown risks of an HIV vaccine, however, some 
Research Ethics Committee representatives were critical about how the legal 
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distinctions made between therapeutic and non therapeutic research restricts 
children‟s participation in HIV vaccine trials, for example: 
 
“[W]e gonna have legal, statutory requirement of the 
National Health Act and capacity to consent (I: under legal), 
ehm, ministerial authority, I mean the concepts, the concepts 
of therapeutic and non therapeutic, invasive and non invasive 
to that whole quagmire (laughter) … but then the whole 
problem relates to legality whether it is therapeutic or it is not 
therapeutic … the statutory criteria may be too restrictive and 
that bureaucracy may hamper progress in research” (REC). 
 
The regulation of informed consent was of concern to half of the Research 
Ethics Committee representatives. This was expressed in the following 
example: 
 
“Process, I am thinking that informed consent when 
eventually it is done how do you confirm misinformed 
consent, how to monitor it, uhm, do we go outside and get 
somebody who is completely independent to come and 
witness the signature …because the guidelines say we should 
have an independent witness and I don‟t think that we‟ve 
been having an independent witness in this group” (REC). 
 
Linked to the monitoring of the Informed consent process was ensuring that 
participants understood what they were actually consenting to. Research 
Ethics Committee representatives felt that part of their task should include 
checking to see how researchers planned to check understanding by 
participants when submitting research proposals, as suggested by a Research 
Ethics Committee representative: 
 
“Maybe that, you know, when we look at protocols we must 
make sure that there is a testing of informed consent you 
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know. I think to me that is very important eh that once you 
obtained informed consent you cant really just take that at 
face value ad that you need to go a step further and test to see 
if this is really informed consent. And you know ask 
questionnaire that your participants have to answer if they 
really know, you know, the truth about what the vaccine is 
going to do” (REC). 
 
One of the problems identified related to the perceived incapacity of Research 
Ethics Committees to monitor the informed consent process:  
 
 “Ja, research ethics committees just don‟t have enough 
capacity [to do audits, checking that procedure is followed]” 
(REC). 
 
Of particular concern to Research Ethics Committee representatives was how 
power dynamics created between wealthy researchers, driven by remuneration 
incentives to run trials, and participants from low socio-economic areas will 
affect the informed consent process. The issue of undue inducements was of 
particular concern in this regard.  
 
“That remuneration issue for me is currently a power issue. 
There is such a lot of money floating around, uhm, for 
investigators who are interested in doing this kind of 
research” (REC). 
  
As with the sponsor representatives, the issue of communication between the 
principal investigators and participants was seen as problematic by the 
Research Ethics Committee representatives. This is clearly seen in the 





“[T]he relationship between the principal investigator and the 
participants is problematic. Its usually mediated by a host of 
other individuals whose training is not necessarily uniform, 
whose background is not necessarily uniform, whose notions 
are not necessarily uniform and whose language, though 
maybe the language of the participants in the study may not 
necessarily be. So, I think there are layers of communication 
breakdown, which are horrific, to be honest and I have got 





















The aims of this study were to explore the perceived ethical challenges around 
informed consent in HIV vaccine trials among a range of stakeholders, to 
compare these challenges to issues raised in ethical guidelines around 
informed consent, and to explore what the factors might be which influence 
the stakeholders perceptions of these challenges. This being a qualitative 
analysis necessitates a discussion of the results of these aims using a more 
narrative approach. In keeping with the general format of this thesis the first 
two aims are discussed in relation to those challenges identified by 
participants in the data under the substantive and procedural elements of 
informed consent whilst the third aim is discussed separately. 
 
4.1. Substantive issues raised by stakeholders 
 
4.1.1. The issue of first person consent: 
 
The question of who should consent to participation in HIV vaccine trials has 
been raised in the literature. These concerns go to the heart of the substantive 
requirement of autonomous decision making by research participants. Writers 
have questioned the insistence on autonomous agency by participants in non 
Western countries (Mkhize, 2006), in cultural settings where cultural norms 
may demand community and/or patriarchal decision making practices where 
the man is perceived to be the ultimate decision maker for the family. Some 
writers (Cash 2006; Diallo et al., 2005; Moodley, 2006) have suggested that in 
developing countries, with a predominant community orientation, first person 
consent to research should be replaced by community consent, usually sort 
from traditional leaders. This trend was not apparent in this data set, however. 





consent should not be replaced by or accompanied by village leaders or heads 
of households some respondents were quite adamant that consent from the 
Induna (tribal leader) should not replace individual consent. Although 
respondents were concerned about community involvement in decisions made 
at the procedural level of informed consent they did not argue for the 
replacement of first person consent by community based consent. 
Respondents argued rather, for clear and transparent communication between 
the researchers and community leaders as a way of facilitating understanding 
to ameliorate potential problems between principal investigators and trial 
participants.  
 
4.1.2. Participants’ capacity to consent: 
 
The demand for transparency in the informed consent process appeared to 
stem from what appeared to be a pervasive lack of trust by respondents of the 
motives of researchers. Two possible reasons for the level of suspicion 
displayed by respondents appeared to be connected to the legacy of apartheid 
and to the perceived over utilization of communities for research purposes. 
Whereas the over utilization of communities for research in developing 
countries by developed countries has been documented (Ekunwe & Kessel, 
1984; Slack, et al., 2004),  research into the effects of apartheid on the 
decision making capacity of black participants to take part in HIV vaccine 
trials is lacking.  
 
The possible influence of apartheid on black participants‟ decision making 
capacity became apparent by the perception of some respondents that mine 
workers, for example, were vulnerable in the face of perceived powerful white 
researchers as, historically, decisions were always made for them.  This 
argument was not shared by all of the respondents, however. A few 
respondents argued that mine workers may be so used to having decisions 
made for them that they preferred it, not from a lack of perceived capacity to 
be autonomous, but more because they were comfortable with the status quo. 
In addition it was acknowledged that mine workers in general preferred to 
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take time to engage in dialogue with their friends before arriving at a decision 
to participate in trials. This is consistent with Russell et al‟s. (2005) findings 
that non westernized participants may require time and the opportunity to 
think about and discuss information with other trusted individuals, before 
reaching a decision.  
 
The ambivalence demonstrated by respondents about the perceived incapacity 
of mine workers, and by extension many other black workers in South Africa, 
asks fundamental questions regarding the theory and practice of informed 
consent in this country. Firstly, is autonomous agency really valued 
universally, or is the complacency to leave decision making to others purely a 
result of the historical influence of apartheid policies? Secondly, what effect 
will the answers to these questions have on the procedural elements of 
informed consent in the South African research context? To begin to answer 
these questions a potential area for investigation would be to ascertain the 
actual perceptions mine workers have in South Africa of their decision 
making capacity and their preferred decision making practices to participate in 
HIV vaccine research. 
 
Respondents raised specific issues regarding South African participants‟ 
capacity to consent. In many instances the perceived vulnerability of 
participants in certain sectors of society was equated with incapacity to 
consent to trials. This “vulnerability discourse” appears to have been used in a 
number of problematic ways by some respondents. First, vulnerability is used 
to justify why women and children, as a result of their perceived vulnerability 
to contract the Human Immunodeficiency Virus, should be included in trials 
and therefore be allowed to give their own consent to do so. Second, 
respondents argued that vulnerable individuals, such as rural women, need 
careful monitoring and mediation before giving their own consent. Third, a 
respondent mounts a slippery slope argument that sees the informed consent 
process as potentially leading to vulnerability and fourth, the low socio-
economic status of many individuals in South Africa was argued to render 
them incapable of knowing their rights and thus incapable of making an 
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autonomous decision to participate in HIV vaccine trials. The question is how 
are these seemingly rational arguments problematic to the notion of informed 
consent? 
 
The first argument suggests that if the research is likely to benefit a group of 
people particularly vulnerable to the disease being researched then this group of 
people should automatically be enrolled in the research on the grounds of their 
perceived vulnerability rather than their actual capacity to consent. Using this 
argument when enrolling children into trials, for example, the principle of 
autonomous agency may be trumped by the principle of beneficence. Although 
Beauchamp and Childress (1994) acknowledge that there are certain instances 
where one biomedical principal can trump another, these need careful 
consideration and balancing.  For instance, one needs to consider that children‟s 
lack of understanding, and therefore, autonomy is what makes them vulnerable 
to exploitation as research subjects which is part of the reason why they are 
legally excluded from participating in non therapeutic trials. The question of 
what age South African children are likely to understand and appreciate the risks 
and benefits about the research to classify them as autonomous agents able to 
consent to trials continues to be debated in the literature (Bester, 1992; Gouws, 
Kruger & Burger, 2000; Wendler & Shah, 2003). 
 
In the second argument respondents questioned the capacity of women to 
consent to HIV vaccine Trials on the basis of the challenges that they face as 
African rural women. The implication of this argument is that women vulnerable 
to the challenges of a rural existence are incapable of thinking for themselves 
and thus need mediation in their decision making capacity. Whilst it is essential 
that researchers need a good understanding of all aspects of the community from 
which they intend to recruit participants (Ekunwe & Kessel, 1984), which may 
require a good grounding on gender empowerment and its interface with HIV, 
care must be taken that researchers do not undermine women‟s real capacity and 
therefore their status to make their own decisions by only recognising the 
capacity of men. This is more likely to happen if researchers assume that 
vulnerability equates to non-autonomy and therefore the inability of vulnerable 
92 
 
participants to make decisions for themselves. Using Beauchamp and 
Childress‟s (2004) understanding that “a person with diminished autonomy is 
in at least some respect controlled by others or incapable of deliberating or 
acting on the basis of his or her desires and plans” (p. 121) may help 
stakeholders in their assessment of whether African rural woman do have 
diminished autonomy or whether it is a matter of others not respecting their 
autonomy.  
 
In the third argument the vulnerability discourse was used to highlight a 
potential conflict between respecting the substantive right to autonomy versus 
respecting the demands of the cultural context in which trials take place. 
Respondents argued that some cultural normative beliefs and practices may 
clash with the demands of first person consent making certain women vulnerable 
to being marginalized or harmed in other ways by their communities if the 
cultural rules are not adhered to. This argument takes the form of a slippery 
slope argument which is essentially saying “If we respect the participant‟s right 
to autonomy it can lead to dire consequences, we assume, and thus we should 
rather do as others demand”. Edwards et al. (2004) would argue that applying 
such faulty logic may act as a smoke screen for paternalism. But, what if women 
were at risk of harm for consenting to trials individually? In such cases, if 
individual participants are made aware of such potential risks during information 
disclosure, they can be given the opportunity to decide for themselves whether 
this represents a personal risk to them and outweighs the benefit of participation. 
Ultimately the decision to participate still lies with the participant and her status 
and autonomy to make her own research decisions is respected and preserved.  
 
The fourth argument uses the vulnerability discourse to support the view that, 
unique to Africa, is the problem of poverty and the tendency of researchers to 
take advantage of poor people perceived as not knowing their rights. Evident 
in this way of thinking is the assumption that vulnerability, caused by socio-
economic factors in this instance, renders individuals ignorant of their rights 
and, by implication, incapable of making autonomous choices.  Not only is 
this deduction erroneous, as according to literature the capacity to be 
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autonomous depends on competence to understand and decide, make 
decisions voluntarily and authorise  ones consent (Appelbaum et al., 1982; 
Beauchamp & Childress, 1994; Ferguson, 2002; Lindegger & Richter, 2000), 
it is insulting.    
 
The above arguments are not meant to imply that there are no legitimate 
problems experienced in the context of vulnerability and informed consent. In 
fact, on the procedural level, issues pertaining to vulnerable persons and 
implementing informed consent processes that are not coercive or exploitative 
was of great concern to respondents. How stakeholders use and understand 
potential participants‟ vulnerability, however, needs to be considered to avoid 
(a) unnecessary exclusion of some participants from HIV vaccine trials; (b) 
allowing inclusion of non-autonomous participants, such as children, into HIV 
vaccine trials, and (c) employing unethical informed consent practices that 
violate individuals‟ autonomy. In addition, more research needs to be done to 
ascertain the actual competence of participants to consent to research from 
vulnerable sectors of society in South Africa. 
 
4.1.3. Children’s capacity to consent to HIV vaccine trials:  
 
The Legal framework under which the trials take place in South Africa has 
been argued to pose a challenge with regards to who gives consent for 
children to consent to HIV vaccine trial participation. Respondents‟ concerns 
regarding children‟s capacity to consent was consistent with arguments raised 
in the literature. As Strode, Slack, Grant and Mushriwa (2005) have argued, 
the National health Act and Children‟s Bill of Rights require that children 
assent to research participation together with their parent‟s formal consent 
when the child is capable of understanding. The difficulty lies in the lack of 
guidelines or suitable testing instruments to help stakeholders determine when 
children have the capacity to understand the research.  
 
With regards to children, other arguments raised by respondents included the 
argument that African children are not comparable to children from the west 
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and thus should not have the same evaluative criteria applied to them when 
considering their capacity to consent to HIV vaccine trials. This argument is 
similar to those posed by Swartz, Kagee, Kafaar, Smit, Bhana, Gray, Lesch, 
Lindegger, Milford, Richter, Seedat, Skhosana and Stein (2005). Problematic 
with this line of argument is that self sufficiency or childhood resilience may 
not equate to meeting the criteria for making informed decisions regarding 
participation in trials. For instance, a 13 year old adolescent who heads a 
household, as so many aids orphans in Africa do, may not have the 
understanding necessary to give informed consent to trials despite his or her 
level of self sufficiency. 
 
In a study focusing on the how those working with South African children 
evaluate the readiness of adolescents for selection into HIV vaccine trials 
Brindley-Richards (2006) recommended that when evaluating the maturity of 
adolescents to participate in trials a range of factors would need to be 
considered. These included psychosocial factors, the adolescent‟s cognitive 
development, self concept, level of motivation, the quality of their 
relationships with their parents and other adults, how effectively they deal 
with peer group influence, how resilient they are and their ability to regulate 
their emotions. In addition, the adolescents‟ talents and abilities, future 
orientation, personality, cultural upbringing, moral and religious development, 
age, risk taking tendencies, the gender of the adolescent, their level of 
education and their ability to take the future into account, were also seen as 
contributing factors. Suitable instruments to ascertain the readiness of South 
African adolescents to independently consent to HIV vaccine trials still need 
to be developed however.    
 
4.1.4. The voluntariness of participants consent: 
 
The substantive requirement of autonomy in consenting to research requires 
that consent is given voluntarily by participants (Beauchamp & Childress, 
1994; Berg, 2001). Respondents were concerned about what effect 
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inducements would have on participant‟s voluntariness to participate in HIV 
vaccine trials particularly in light of pervasive poverty. Due to a lack of 
empirical studies on the concept of and complexities of voluntariness 
(Barsdorf & Wassenaar, 2005) in the informed consent process, however, 
limited clarity has been provided as to what actually constitutes voluntary 
consent to research and what types of ethical transgressions are likely to 
undermine voluntariness (Pace & Emanuel, 2005). Research needs to be done 
on how various types of research rewards influence low socio economic 
participants decisions to participate in HIV vaccine trials in the South African 
context.   
 
4.2. Procedural concerns raised by stakeholders: 
 
Demographically South Africa is a multicultural society with a diverse range 
of cultural beliefs and practices that impact on the procedural elements of 
informed consent. A number of concerns were raised by respondents about the 
implementation of informed consent in HIV vaccine trials. These concerns 
were consistent with many of the procedural concerns covered in the 
literature.  
 
Despite the fact that Forde and Vandvik (2005) argue that issues relating to 
patient information and communication are generally given low priority, the 
data from this study did not reflect this. Consistent with UNAIDS guidelines 
for HIV vaccine research, a process of consultation between community 
representatives, researchers, sponsor(s) and regulatory bodies, was seen as 
essential by the respondents.  
 
With understanding or comprehension being a central issue in informed 
consent, together with the social, political, cultural and linguistic differences 
of the South African population as compared to those of the west, it is not 
surprising that it was raised as an issue of real concern for all the stakeholders. 
Issues relating to information disclosure, communication and participants‟ 
understanding of the information given them, were primary concerns 
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consistent with those concerns reflected in the literature. Beauchamp and 
Childress (2001) and Lindegger and Richter (2000), for example, have argued 
that participant‟s understanding of the information disclosed to them is a key 
issue in Informed consent.  
 
4.2.1. Participant understanding: 
 
With there being eleven official languages in South Africa the issue of 
participants understanding the material given to them, particularly if delivered 
in a language that is not their first language, was of concern to respondents. In 
this regard issues relating to the translation of information from one language 
to another were of most concern. In addition to the common concerns 
reflected in the literature, that some languages do not have words to describe 
certain scientific jargon (Moodley, 2002; Gasa, 1999), affecting what Bayer 
(2000) refers to as semantic understanding, respondents argued that certain 
questions could loose their true meaning when translated, yielding answers 
that may not accurately reflect the participants real understanding of the 
information. Linked to this was the problem of using translators from different 
areas who do not share the same vernacular of the language used in the area 
from which participants came. This was consistent with concerns raised in the 
literature (Moodley, 2002).  
 
Respondents were divided about how much information to include on consent 
forms, as well as participants understanding of them. Concerns that 
participants may not understand complicated and lengthy informed consent 
forms were consistent with Epstein and Lasagna‟s (1969) findings. When 
deciding on how much information to give participants respondents gave 
mixed messages, reflecting the ambivalence in the literature. While some 
respondents argued that participants should be given all trial relevant 
information, not necessarily to satisfy the minimum standard of what 
participants of HIV vaccine trials should understand, as highlighted by 
Lindegger and Richter (2000), but to ensure that participants received the 
information they needed in case the motivations of researchers could not be 
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trusted, other respondents were in agreement with Iselfinger (1972) and 
Lindegger et al. (2006) that discussing irrelevant hypothetical risks to 
participants provides excess information that may distract the participant from 
the information needed for informed consent.  
 
While there should be some mindfulness of the suspicions some stakeholders 
have of researchers‟ motives, due in part to the effects of apartheid and over 
utilization of black populations for research, Lindegger et al. (2006) warn that 
while providing participants with all the information about trials may satisfy 
the legal requirements of disclosure of information the ethical condition of 
understanding in order to make decisions in one‟s own best interest may not 
be satisfied because of the volume of information participants need to 
understand.  
 
Linked to the understanding of the material disclosed to participants was the 
issue of what assessment procedures should be used to assess participant‟s 
understanding. The literature cites a number of questions regarding the 
different methods used to assess participant‟s understanding. Lindegger and 
Bull (2002), for example, question the use of formal tests of knowledge to 
assess participant understanding “in research conducted in less formally 
educated, culturally diverse or developing country contexts” (p. 4). Further 
complicating the issue is that understanding is an elusive concept and it is not 
easy to evaluate the nature and level of understanding that individuals have of 
a concept, event or process (Lindegger & Richter, 2000). Whereas it may be 
relatively easy to evaluate the adequacy of the information disclosed to 
participants “it is far more difficult to assess whether and how the information 
and its implications are truly understood” (p.315). The danger of using 
relatively easy formal assessment practices was elucidated in this data set 
where a respondent found the practice of using yes/no questioning, in one of 





While respondents agreed that assessing understanding must be done on an on 
going process, they suggested using different methods of assessment for 
different communities, such as using a feedback mechanism where 
participants are asked to repeat the information given to them back to the 
educator. The implication was that assessing understanding needs to be more 
context specific to accommodate cultural differences in understanding. These 
views fit well with those expressed by Lindegger et al. (2006). Exactly what 
these community specific variables are that require participants‟ 
understanding to be assessed differently is unclear and is an area of research 
that may require further investigation.  
 
The general lack of education and training of stakeholder groups expected to 
educate the community about trials was of concern to respondents. If 
information disclosure about the trials is to be part of the responsibility taken 
on by Community Advisory Board members, for example, then clearly they 
themselves need to be well informed about what and how much information is 
required for participants to consent. Poor understanding of the knowledge 
educators must impart to the community potentially results in misinformation 
about trials affecting the quality of informed consent. Exactly how 
knowledgeable stakeholders need to be to produce adequately informed 
participants is unclear and needs further investigation.  
 
Providing this training to Community Advisory Board members in addition to 
the stakeholders already directly involved in educating the community poses 
extra financial challenges to trial sites with existing poor resources. An 
existing lack of communication and coordination within and between 
stakeholder groups in the provision of this training was of concern to 
respondents. What type and amount of information to include and who should 







4.2.2. Information disclosure: 
 
The role the media can play in disseminating information about HIV vaccine 
trials to enhance community awareness was acknowledged by respondents 
who expressed concern about the poor media coverage about trials. A number 
of challengers were highlighted by the media representatives in disseminating 
information about the trials. Challenges pertaining to HIV vaccine trials/ 
AIDS fatigue, the tension between sensationalizing HIV vaccine related 
stories to sell newspapers as against reporting the facts, and reporting difficult 
scientific information about HIV vaccines in a way that the public will 
understand, was consistent with those highlighted in the literature (Hanefeld, 
Coates & Kruger, 2005; Cullinan, 2001; Swanepoel, Fourie & Froneman, 
2005).  
 
In addition, some respondents portrayed the media as callous and cold. This 
was despite evidence in the data that showed a degree of compassion and 
virtuosity in some media representative‟s ethical decision making capacity 
when reporting on HIV vaccine trials. This reflects Swanepoel, Fourie and 
Froneman‟s (2005) concerns regarding the negative impression created by the 
press when reporting on HIV/AIDS and HIV vaccine trials. The negative 
perception some stakeholders have of the media may prevent the development 
of the symbiotic relationship needed between the press and the stakeholders, 
however, to enhance trial related information dissemination to the public. 
 
Evident in the data was respondents‟ apparent lack of knowledge about, use 
of, or access to the ethical guidelines set out for HIV vaccine trials. The lack 
of knowledge and subsequent use of the ethical guidelines by stakeholders 
may have a negative impact on the application of the informed consent 
process at the levels of both pre-trial education and information disclosure to 
participants. If stakeholders do not know the legal and ethical requirements of 
the informed consent process how can they ensure that participants meet the 
requirements of what they should understand as set out in the informed 
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consent protocols? Further more, on a procedural level, lack of consensus 
between stakeholder groups on how to implement the informed consent 
process is likely to affect uniformity across HIV vaccine trials in the country. 
Exactly how much knowledge South African stakeholders of HIV vaccine 
trials have of these guidelines and or the reasons why they are not utilized 
needs further investigation. 
 
This section has attempted to discuss respondents concerns in relation to 
theoretical arguments portrayed in the literature and the implications they may 
have for both ethical theory and the practice of informed consent.  A number 
of concerns about informed consent similar to those reflected in the literature 
were highlighted. These concerns were discussed in relation to both the 
substantive and procedural elements of informed consent. Substantive 
concerns related mainly to the issue of first person consent, participant‟s 
capacity to consent and whether participants consent voluntarily.  
 
Of particular interest was the way in which respondents tended to use what I 
have referred to as “vulnerability discourse” in potentially problematic ways. 
First, vulnerability was used to justify why women and children, as a result of 
their perceived vulnerability to contract the Human Immunodeficiency Virus, 
should be included in trials and therefore be allowed to give their own consent 
to do so. Second, respondents argued that vulnerable individuals, such as rural 
women, need careful monitoring and mediation before giving their own 
consent. Third, a respondent argued that the informed consent process itself 
potentially leads to vulnerability and fourth, the low socio-economic status of 
many individuals in South Africa was argued to render them incapable of 
knowing their rights and thus incapable of making an autonomous decision to 
participate in HIV vaccine trials. Procedural concerns related to information 
disclosure, participants‟ understanding of information disclosed, including 
how to assess their understanding, issues around cultural sensitivity, and the 
regulation of informed consent. In addition, some issues emerged as being 
specific to the South African context, such as the impact of apartheid on 
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participants‟ perceived capacity to consent to trials, and its impact on 
stakeholders‟ perceptions of informed consent in HIV vaccine trials.  
 
4.3. The variables impacting on the positions taken by stakeholders: 
 
The third aim of this study was to explore what the factors might be which 
influence the stakeholders‟ perceptions of these challenges. A number of 
possible factors which appeared to underlie the positions stakeholders 
appeared to take will be discussed next.  
 
4.3.1. The role of stakeholders 
 
As mentioned, part of the aims of this study was to determine what variables 
impact on the position stakeholders take on the issue of informed consent. In 
addition to how stakeholders use vulnerability discourse (discussed earlier), 
other variables appeared to be related to the role of different stakeholders in 
trials, the philosophical position underpinning their ethical viewpoints, and 
respondents‟ views about the universality or relativity of ethical issues in 
research.  
 
It would appear that the roles stakeholders have within the trials impacts on 
the position they take with regards to Informed consent. From the data it 
became apparent that Community Advisory Board members see themselves as 
mediators between the researchers and the community. This was consistent 
with Moodley‟s (2002) views on the importance of using advisors from the 
communities to represent communities in research. Whilst they acknowledged 
their educative role there appeared to be an underlying paternalistic sense of 
responsibility felt by Community Advisory Board representatives to make 
certain decisions on behalf of the community. With their main concerns 
centered on issues of community and participant exploitation by researchers 
they may fall into the trap of underestimating the true capacity of community 
members to make their own individual decisions to consent to trials.  In fact, 
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some respondents questioned the validity of using Community Advisory 
Boards as mediators of community decisions to participate in research, 
showing scepticism about their competence and representativeness of the 
community. Their concerns reflect the concerns raised by IJsselmuiden and 
Faden (1992) who question the identification of community representatives 
genuinely trusted by communities. Some investigation needs to be done into 
Community Advisory Board members‟ levels of competence, to what degree 
they do represent the community‟s views regarding HIV vaccine trials in 
South Africa and what their actual responsibilities are. 
 
The Civil Society representatives appeared to perceive their responsibility as 
operating on a broader macro level. They see themselves more in terms of 
being protectors of society so they were much more concerned about the 
vulnerable groups in society and their capacity to consent. Their perceived 
role as protectors of society impacted on the way they view informed consent 
in that they were more likely to advocate a need for structure and continuous 
monitoring of the process of informed consent. Interestingly the 
representatives of this group were more familiar with existing ethical 
guidelines than most other groups were.  
 
With the Site Staff having direct contact with participants at trial sites they 
face the practical task of ensuring that the informed consent process is carried 
out competently and ethically, according to protocol. Their role pertains to 
implementation which requires a good foundational knowledge of the ethical 
guidelines that need to be adhered to as well as an understanding of the issues 
identified in the literature around cultural sensitivity (Bayer, 2000; Lindegger 
et al., 2006; Moodley, 2002). When site staff are faced with the complexities 
of applying standardised informed consent protocols to all participants who 
vary considerably in their notions of personhood (IJsselmuiden & Faden, 
1992; Mkhize, 2006) cultural understanding and cultural norms, it may 




The trial staffs‟ abilities to identify and resolve problems encountered at trial 
sites better than other stakeholders was acknowledged. The perception of most 
stakeholders was that site staff knows the community, the language and the 
culture of participants and is therefore better able to manage the procedural 
expectations of informed consent. Whether this perception is correct is an area 
needing further investigation. What is evident is that if researchers are to gain 
perspective about the practical complexities of implementing complex 
informed consent procedures, so that ongoing improvement can occur 
continued communication between stakeholder groups is essential. 
 
The monitoring of ethical standards related to informed consent was perceived 
to be the responsibility of Government. This monitoring process was 
perceived as the main role of Research Ethics Committees. There were 
concerns that the over regulation of informed consent, however, could hamper 
trials if context related problems in informed consent procedures are not 
allowed to be amended to suit the context. There appeared to be a lack of 
consensus between stakeholder groups about whether informed consent 
should be regulated.  
 
Although the media‟s role was viewed as mainly educative, the potential of 
the media to serve an additional regulatory role that challenges stakeholders to 
run trials in accordance with protocol was recognised. In relation to informed 
consent the media‟s policing role was advocated for the purpose of giving 
participants a forum in which to complain if they felt their consent was not 
legitimate. The ability and or preferences of South African participants to 
make use of such a forum is a topic for investigation.   
 
The main role of the trial sponsors is to provide the resources needed to 
conduct the trials. Not surprisingly they expressed concern about the slow 
pace of trials. A fear was that if trial sponsors take what they perceive to be 
trivial matters about informed consent to the ethics committee involved this 
would delay trials. Pushing trials to go ahead at a pace that does not fully 
address all the potential ethical issues pertaining to informed consent, 
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however, may not be within the best interests of participants, stakeholders or 
the trial sponsors. Infringements of legal ethical guidelines may stop trials 
permanently and in effect, not only waste valuable resources, but seriously 
delay finding a solution to HIV/AIDS in the form of an HIV vaccine. How 
significant the procedural concerns stakeholders have regarding informed 
consent need to be to warrant the research ethics committee‟s involvement 
needs consideration. 
 
4.3.2. The philosophical ethical positions adopted: 
 
Stakeholders‟ ethical viewpoints on informed consent revealed different 
philosophical positions, which may affect the way they view the 
implementation of informed consent. Both the government and the 
Community Advisory Board representatives appeared to take a more 
paternalistic ethical approach that aims to protect communities. The impact of 
functioning from a paternalistic ethical framework on the informed consent 
process, however, has the potential to violate the substantive requirement of 
autonomous agency by participants if decisions are made for competent 
individuals to consent or dissent to trials on their behalf.  
 
Civil society representatives appeared to advocate that all HIV vaccine trials 
in South Africa follow strict protocols when obtaining consent from 
participants. This was mainly to protect individuals from being used as a 
means to researcher‟s ends. This deontological ethical stance (Moodley, 2006) 
may explain why stakeholders from the civil society group generally expect 
universal ethical norms and standards to be applied to all participants 
engaging in the informed consent process, together with strict monitoring of 
this process, as a way of guaranteeing protection of all participants regardless 
of their inherent differences.  
 
Site staff representatives appeared to take a descriptive relativist ethical stance 
to the process of informed consent in that there was recognition that “different 
people have different moral beliefs which affects how they behave and define 
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problems” (Pack-Brown & Williams, 2003, p. 36). This philosophical ethical 
framework may be influenced by the role site staff have in implementing the 
informed consent process. Taking into consideration the different cultural and 
moral perspectives participants may have (Pack-Brown & Williams, 2003) 
site staff may be particularly concerned about the relational impact 
individualized consent practices may have on family structures and the wider 
collective community (Mkhize, 2006) which in turn may impact on, and be 
impacted by, the procedural demands made by the informed consent process. 
 
Some Media representatives appeared to be concerned about the consequences 
of trial participation and the consequences of the way journalists potentially 
violate participants‟ confidentiality in their representation of HIV vaccine 
trials in the media. Their concern related to the possibility that participants‟ 
consent was not truly informed if they were not made aware of these possible 
violations to their confidentiality and the consequences that may result. These 
media representative‟s concerns appear to reflect a deontological ethical 
framework that is concerned about participants‟ individual rights. Their 
deontological ethical stance may explain the tension they experience when 
reporting facts about HIV vaccine trials since it conflicts with the utilitarian 
outlook of media houses who want sensationalised stories about trials to sell 
newspapers. This tension felt by reporters highlights the tension between 
deontological and utilitarian approaches to ethics mentioned in the literature 
(Alexander & Moore, 2007; Hooker, 2007). 
 
The concern about the slow pace of trials by trial sponsor representatives was 
a good demonstration of utilitarian concern as it highlights the tension 
between proceeding cautiously, according to the rules (Deontology), which 
holds back trials, and completing trials as quickly as possible to arrive at a 
solution, which potentially could save millions of lives (Utilitarianism). A 
utilitarian ethical outlook by trial sponsors may create pressure on other 
stakeholders to proceed with trials without full consideration of the ethical and 
practical dilemmas inherent in informed consent in trials of this magnitude. 
Stakeholders may find it difficult to negotiate the tension between the 
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deontological need to protect participants‟ rights to fully informed consent and 
the utilitarian need to proceed with trials as quickly as possible. 
 
The Research Ethics Committee representatives indicated a number of 
different ethical positions that may inform their views on informed consent in 
HIV vaccine trials. A possible virtue ethical understanding of informed 
consent was evident in the expectations some Research Ethics Committee 
representatives had that stakeholders should be honest and virtuous. Others 
showed a possible consequential ethical concern about whether the costs of 
participation in trials outweigh the benefits for participants and whether they 
understand the personal implications of these costs. In addition, others 
demonstrated an intentionalist ethical framework concerning the motivations 
behind why participants consent to trials as well as the motivations of 
principal investigators who run HIV vaccine trials. The variety of 
philosophical and ethical positions held by Research Ethics Committee 
members may be reflective of their primary task to discern whether there are 
any ethical transgressions in the research protocols they evaluate that may 
violate the informed consent process. 
 
In summary, both the government and the Community Advisory Board 
representatives appeared to operate from a concerned paternalistic ethical 
framework. The Civil Society representatives appeared to demonstrate a 
deontological ethical position. Media representatives appeared to be 
concerned about the consequences of trial participation as a result of the way 
journalists represent HIV vaccine trials in the media. Their consequentialist 
viewpoint reflects a deontological concern about participant‟s rights and 
highlighted the tension journalists feel when having to negotiate the utilitarian 
ethical stance used by some media houses to justify selling newspapers. Trial 
sponsor representatives, on the other hand, appeared to demonstrate a 
utilitarian concern in trying to move HIV vaccine trials along at a much faster 
pace. The Research Ethics Committee representatives indicated a range of 
different ethical positions that included consequentialism and intentionalism 
and a virtue ethical understanding towards informed consent, whilst  Site staff 
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representatives appeared to take a descriptive relativist ethical stance that 
gives cognisance to the different views held by participants. 
 
The implication of stakeholders‟ viewing informed consent from these 
different philosophical and ethical theoretical perspectives is that tension may 
exist between stakeholders when making decisions. The tension between 
different ethical theoretical perspectives was implicitly evident in some 
responses made by the respondents. The tension between deontological ethics 
and utilitarianism, for example, appeared to cause conflict between 
stakeholders when making decisions as to whether to protect individual rights 
or the public good. On a procedural level, where, for example, an absolutist 
and/ or deontologist may expect rigid adherence to legal protocols for 
informed consent, descriptive and normative relativists  and utilitarians may 
insist on more flexible procedures that are more accommodating to the 
cultural beliefs and norms presented by participants and perceived overall 
societal benefits. This tension may also cause ambivalence within individuals 
who may be uncertain about their ethical perspectives. Furthermore when 
different members within a Research Ethics Committee hold different views 
about the informed consent process it may hamper the speed at which research 
protocols are agreed upon which in turn may cause some of the delays that 
concern and frustrate other stakeholders.  
 
4.3.3. The Universality versus relativity of informed consent:  
 
 Respondents views about the universality or relativity of ethical issues may 
impact on the position Stakeholders take with regards to informed consent. 
When considering the issue of universality versus  relativity of ethical theory 
and practice in research Pack-Brown and Williams (2003) suggest that it is 
always pertinent to ask how Western/monocultural and muliticultural 
perspectives are similar and different. When reviewing these perspectives in 
terms of the informed consent process in HIV vaccine trials, a 
Western/monoculture approach, based on mainstream American values and 
beliefs, is likely to place value on individualism and autonomous agency as 
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well as the legal protection of individual participants and researchers. From a 
multicultural approach, there is likely to be more focus on the importance of 
“subjective relationships that focus more on people than on progress, more 
emphasis on sharing and cooperation for the good of all those involved and 
more emphasis on community needs than on individual needs, all of which 
contribute to the underlying social and spiritual importance of harmony and 
balance” (ibid, p. 194). From these two perspectives, the monocultural 
approach is likely to insist on first person consent rather than proxy or 
community based consent advocated by a multicultural approach.   
 
 Using Pack-Brown and Williams‟ (2003) dichotomised approach, 
stakeholders who follow a monocultural perspective to ethical research are 
likely to maintain that ethical principles like informed consent are universal 
and therefore the same protocols should be practiced where ever the research 
is taking place. Those ascribing to a multicultural approach, on the other hand, 
are likely to argue that the informed consent process should be adapted to the 
unique context relevant to the population being researched.  
 
Furthermore the perceived universality or relativity of ethical challenges in 
HIV vaccine trials by the respondents is likely to be informed by the 
philosophical and ethical theoretical positions they hold. Those with a 
deontological perspective, for example, are likely to view informed consent as 
universally applicable, since it hinges on the principle of autonomy, whereas 
those ascribing to a utilitarian ethic are likely to view informed consent 
practices as relative to whether it benefits the particular context. 
 
All the respondents of this study were asked whether they thought the ethical 
issues they identified were universal or unique to South Africa. The responses 
given by most of the respondents within all the groups were not consistent 
with Pack-Brown and Williams (2003) expectations that researchers would 
see monocultural versus multicultural perspectives in such a dichotomous 
way. What became evident was the tendency for respondents to accommodate 
both perspectives in one viewpoint. This  broad approach that attempts to 
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accommodate both a universal and relativist conceptualization to informed 
consent is more consistent with what Benetar, (2004) refers to as taking a 
reasoned contextual universal approach to informed consent. 
 
Taking a reasoned contextual universal approach to informed consent may be 
based in part on an awareness stakeholders may have of the different notions 
of personhood that exist in the multicultural society present in South Africa. 
Using such a broad approach is likely to ainformed consent that takes into 
account the different arguments regarding, for example, notions of 
personhood described in the literature (Lindegger, 2002; Hart & Lindegger, 
2002; Mkhize, 2006; IJsselmuiden & Faden, 1992; Christakis, 1988; Barry, 
1982; Taylor, 1979; Willett, Kilama &  Kihamia, 1979; Shapiro & Stein, 
2004; Gasa, 1999) as well as the demand that the Medical Research Council 
(2003) and UNAIDS (2000) guidelines have placed on researchers to 

















5.1. Limitations of the study: 
 
The main limitation of this study was the small sample size. Some previous 
studies exploring perceptions of ethical concerns in HIV vaccine trials have 
used larger samples and closed ended questionnaires. However, in this study it 
was explicitly decided that it would be preferable to conduct an indepth study 
with a small sample of stakeholders. Further, the unavailability of some 
members making up stakeholder groups, for example only two government 
and three research ethics committee and only one trial sponsor representative, 
makes this an even more limited sample. Clearly there can be no widespread 
generalization of the findings of this study. However, the findings do raise a 
number of critical issues as far as the implementation of informed consent in 
HIV vaccine trials is concerned. 
 
There were also some practical limitations of the study. Although, as Kvale 
(1996) suggests, the interviewing process offers the researcher an opportunity 
to begin the emersion process whilst collecting the data, words and phrases 
inaudible on the taping were difficult to decipher. Thus some meaning may 




This study formed part of a larger study done by the HIV /AIDS Vaccine 
Ethics Group which aimed to provide information to aid the South African 
Aids Vaccine Initiative‟s objective of investigating the ethics of HIV vaccine 
trials.  The three main aims of this study were to explore stakeholders 
perceptions of ethical challenges around informed consent in HIV vaccine 
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trials, and to explore what the factors might be that influence the stakeholders 
perceptions of these challenges.  
 
According to debates raised in the literature on informed consent in medical 
research, a number of contentious issues were expected to be raised by 
stakeholders partaking in HIV vaccine trials. These issues related to 
substantive elements such as the autonomous capacity of participants to give 
first person consent, challenges around child and adolescent consent, and the 
voluntariness of participants‟ consent, and procedural elements such as 
participant understanding, communication, information disclosure, the 
regulation of informed consent, and the impact of context on the informed 
consent process. Would South African stakeholders‟ anticipate additional 
challenges to informed consent in HIV vaccine trials in the South African 
context? In light of Lindegger et al‟s. (2006) argument that the populations 
needed for Phase III trials are populations at high risk of HIV infection and 
are also commonly characterised by high levels of poverty, relatively low 
levels of formal education, and poor access to resources, would South African 
stakeholders‟ concerns differ from those already raised in the West? Since 
many of these debates remain hypothetical, it was considered important to ask 
South African stakeholders involved in HIV vaccine trials what their concerns 
were.   
  
On examination of the findings, the main concerns around informed consent 
expressed by the stakeholders were consistent with issues already identified 
and debated in the literature.  When considering the capacity of participants in 
the South African context, stakeholders debated whether vulnerable 
participants could be considered fully autonomous and thus able to give first 
person consent or whether proxy or community consent should be sort; 
whether the capacity of South African children, perceived as more resilient 
and mature because of the difficulties they are exposed to, should be evaluated 
using the same criteria as those used on western children; and whether 
vulnerable participants would be even more vulnerable to the influence of 
inducements for participation because of their poor socio economic status. On 
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a procedural level, stakeholders were concerned about the challenges they 
faced when trying to implement informed consent according to what was 
required by ethical guidelines. Stakeholders had the same concerns identified 
in the literature pertaining to information disclosure and the education of 
participants, ameliorating language barriers, disclosing information in a way 
that participants could understand, assessing participant understanding, 
facilitating community involvement from before the trials starts as a means of 
empowering the community in preparation for HIV vaccine trials, reducing 
possible stigmatization of participants, enhancing the relationship between 
researchers and participants through communication and dealing with issues 
related to cultural norms and practices that may clash with legal requirements. 
  
Stakeholders raised some additional issues not reflected in the literature. The 
perception was that socio-economic issues in Africa are qualitatively different 
from those in the West, rendering African participants more vulnerable and 
therefore in need of more protection during the informed consent process. Of 
particular concern was how power dynamics will affect the informed consent 
process particularly with regards to communication between the principal 
investigators and the participants. The perceived power of the community was 
also interesting. In some instances, not only was the community perceived as 
more powerful than the law in terms of who should consent for children, but 
the community was seen to have the power to stigmatize participants known 
to be involved in trials. And yet at the same time stakeholders were concerned 
about the voluntariness of participants consent. The emphasis put onto 
community by stakeholders may be a reflection of the communitarian 
worldview of many traditional African people. The level of suspicion raised 
about the motives of researchers was not surprising considering South 
Africa‟s history of apartheid and the tendency of developed countries to take 
advantage of research populations in developing countries. What was 
surprising however, was the extent of stakeholders‟ levels of suspicion. 
Stakeholders were concerned that parents would exploit their own children, 
putting their needs in front of their children‟s needs, by forcing them to 




Identifying the variables that may impact on the position stakeholders take on 
the issue of informed consent was also part of the aims of this study. Factors 
such as the role the respondents play within the trials, the philosophical 
position underpinning their ethical viewpoints, the way in which respondents 
use the vulnerability discourse, and their views about the universality or 
relativity of ethical issues was speculated to impact on the position they take 
with regards to informed consent. The impact of these variables on the 
implementation and theory of informed consent together with opportunities 





The perceptions stakeholders in this study expressed about the vulnerability of 
South Africans is potentially problematic for recruitment of participants into 
HIV vaccine trials and the informed consent process. If potential participants 
are perceived of as vulnerable and are incorrectly deemed to be non-
autonomous agents, they may either be excluded from participation 
unnecessarily or have their autonomy usurped by proxy consent.  Assessment 
procedures assessing participants‟ real capacity to consent, to prevent unfair 
discriminatory practices that override personal autonomy or exclude people 
from participation in HIV vaccine trials, need to be researched and 
formulated. Of particular importance is the development of suitable testing 
instruments to ascertain the readiness of South African adolescents to 
independently consent to HIV vaccine trials.    
 
Research into the effects of apartheid on the decision making capacity of 
black participants to take part in HIV vaccine trials is lacking. Investigation 
into the actual perceptions of mine workers on their decision making capacity, 
and their preferred decision making practices, may begin to answer the 
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question of the extent to which apartheid policies have impacted on black 
South African research subjects decision making.  
 
As highlighted by Pace and Emanuel (2005) limited clarity has been provided 
on what actually constitutes voluntary consent to research and what types of 
ethical transgressions are likely to undermine voluntariness. Additional 
research in the context of HIV vaccine trials in South Africa regarding what 
constitutes undue-inducements, for example,  and how various types of 
research rewards influence low socio economic participants decisions to 
participate could be of assistance.  
 
The potential value of having representatives of communities to assist the 
informed consent process in HIV vaccine trials cannot be overstated. 
However, considering the concerns some respondents had regarding 
Community Advisory Board member‟s representativeness of their community, 
their actual knowledge base of HIV vaccine trials, and  their ability to 
adequately disseminate such information to potential participants,  
investigation into these factors as well as defining what their actual 
responsibilities are needs to be done to improve and capitalize on this valuable 
resource.  
 
Similarly, stakeholders believed that the staff working at different HIV 
vaccine trial sites know the community, the language and the culture of the 
research participants and are therefore better able to manage the procedural 
expectations of informed consent. Whether this perception is correct is an area 
needing further investigation.    
 
Negotiating the demands imposed by the interface between multi-cultural 
beliefs and practices and the often westernised legal requirements set out in 
guidelines, is concerning to the stakeholders of this study. More research that 





The slow pace of HIV vaccine trials was a concern to stakeholders for various 
reasons. A fear expressed was that if trial sponsors take what they perceive to 
be trivial matters about informed consent to the ethics committee involved it 
would delay trials even further. How significant the procedural concerns 
related to informed consent, in the South African context, need to be to 
warrant the research ethics committee‟s involvement is an area that needs 
clarification. 
 
The adequacy of training given to Stakeholders to provide the information 
necessary for informed consent was questioned.  Exactly how knowledgeable 
stakeholders need to be to produce adequately informed participants is unclear 
and needs further investigation. In addition, what type and amount of 
information to include and who should provide this training needs to be 
clarified. 
 
In relation to information disclosure investigations into the impact of 
complicated and lengthy informed consent forms on participants in the South 
African context may be of value when considering how much and what type 
of information to include on informed consent forms.  
 
Using the media as an additional regulatory body that provides participants 
with a forum in which to complain if they feel their consent to participate in 
HIV vaccine trials has been violated was suggested.  The ability and or 
preferences of South African participants to make use of such a forum, 
however, is a topic for investigation.  
  
Although the Medical Research Council requires that international human 
rights laws/norms and standards should be considered, some respondents 
argued that there is no elaboration of what these are. Respondents indicated 
that international norms and standards must be expanded to the South African 
situation. Research that addresses what these norms and standards are is likely 
to give stakeholders more clarification on how to apply them.  Benatar, (2004) 
suggests researchers take a reasoned contextual universal approach when 
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considering when and how it is morally appropriate to take local contexts into 
consideration in applying universal ethical principles. Researchers should 
consider whether local cultural values inflict harms that could and should be 
avoided (or are harmless) and whether (or not) they infringe on human rights 
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